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ABSTRACT 
 
 
Follicle stimulating hormone (FSH) and luteinizing hormone (LH) are 
glycoprotein gonadotropins from the anterior pituitary gland that are involved in 
reproductive functions.  They are heterodimeric proteins that share a common α-subunit 
that is highly conserved amongst mammalian species, and is also conserved across this 
family of proteins.  The β-subunit confers receptor specificity and is distinct.  
Recombinant gonadotropin expression would be an important advance for the bovine 
superovulation industry, as there are a number of disadvantages associated with the 
currently used pituitary-derived gonadotropins.  For example, these pituitary products are 
contaminated with other proteins including hormones, exhibit batch-to-batch 
inconsistencies, and harbor the potential to spread disease-causing agents.  Recombinant 
preparations can overcome these negative issues because they are potentially free of 
contaminating proteins.  Further, recombinant gonadotropins can be produced so they 
have no potential to transmit harmful agents. 
Here, two heterologous systems, bacteria and yeast, have been surveyed for their 
utility in the production of recombinant bovine FSH and LH (bFSH and bLH, 
respectively).  bFSH was tested using a rat ovarian weight gain assay to determine 
biological activity and preliminary results indicate that the bacterial-derived bFSH had 
activity.  The activity of yeast-derived bFSH could not be determined as a result of 
complications with the rat assay. 
   bLH was assayed using bovine granulosa cells treated in vitro with LH for one 
day, followed by gene transcript profile analysis to characterize receptor binding and 
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activation.  Both recombinant preparations reduced expression of FSH receptor transcript 
levels similar to pituitary LH, as expected.  Both the pituitary LH and yeast LH decreased 
transcript expression of LH receptor by 7.0-fold and 2.9 fold (respectively), suggesting an 
autocrine down-regulatory effect.  Notably, the bacterial preparation failed to yield 
similar results (1.2-fold decrease), potentially because of the differences in post-
translational modifications that have been suggested to be important for protein 
bioactivity.  
Recombinant bLH was also used in a rat ovarian ascorbic acid depletion bioassay 
to determine the impact of the compound at the whole animal level.  Preliminary data 
suggests there was an ovarian ascorbic acid increase with both pituitary and recombinant 
LH treatments, rather than the expected decrease.  Interestingly, the vehicle control 
caused an ascorbic acid increase for unknown reasons.  While both the bacterial bLH and 
yeast bLH treatments resulted in an overall increase in relative ascorbic acid content post-
LH treatment, the concentrations were less than the vehicle-only control, suggesting an 
overall reduction possibly as a result of activity maintained by the recombinant protein.         
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1 
CHAPTER ONE 
 
LITERATURE REVIEW 
(portions of this section are published in Reproduction in Domestic Animals, ePub March 
2011) 
Recombinant Gonadotropin Production 
 Recombinant proteins are produced from a heterologous host using molecular 
cloning techniques.  Recombinant protein production and usage first became 
industrialized with the production of human insulin from a bacterial host in the early 
1980s for control of human Type I diabetes (Johnson 1983).  Unlike gonadotropins, 
insulin is not post-translationally glycosylated, making heterologous expression in 
bacteria relatively straightforward.  Following insulin, a myriad of recombinant proteins, 
including recombinant gonadotropins, have been produced, but high quality and 
inexpensive recombinant hormone production remains challenging in part due to protein 
glycosylations. 
Initially, recombinant gonadotropins such as follicle stimulating hormone (FSH) 
were produced as two separate subunits oligomerized after synthesis (Kaetzel et al. 1985; 
Keene et al. 1989).  Later efforts included studies aimed at the expression of constructs 
that yielded both protein subunits fused together, which quickly became the standard 
production method because it required fewer steps during synthesis and purification 
(Olijve et al. 1996; D'Antonio et al. 1999).   
 The next focus of recombinant gonadotropin research included efforts to modify 
the subunits to yield increased in vivo biological half-life (and therefore decrease the 
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number of doses required for adequate superovulation).  By engineering up to four extra 
N-linked glycosylation consensus sites into the α-subunit (fused to the β-subunit), 
retention time was enhanced (Perlman et al. 2003; Trousdale et al. 2009).  Increased 
retention time has also been achieved by adding a section of DNA that codes for a highly 
glycosylated protein to one terminus of the protein; the most common of these being the 
carboxy-terminal peptide (CTP) of human chorionic gonadotropin (hCG).  The CTP has 
been shown to cause a ~ 4-10-fold increase in biological half life in humans (Fares et al. 
1992; Devroey et al. 2004; Fauser et al. 2009).  The chimeric recombinant human FSH 
(hFSH-CTP) facilitated follicular maturation 50 hours after the initial dose, comparable 
to four injections of pituitary-derived hFSH delivered 12 hours apart (Fauser et al. 2009).  
The increased retention time may be due to the extra negatively charged sialic acid 
residues incorporated into the O-linked glycosylations within the CTP molecule.  Acidic 
residues tend to have reduced glomerular filtration in the kidney and a protective effect 
within the liver (Fares et al. 1992; D’Antonio et al. 1999; Fauser et al. 2009).  Further, 
Matzuk et al. (1990) demonstrated that the biological activity of hCG was severely 
impaired with the removal of the CTP region.  Garcia-Campayo et al. (1997) extended 
the biological activity of human luteinizing hormone (hLH) by the addition of the CTP 
region.  
More recently, researchers have developed fused α and β constructs that have the 
ability to bind to multiple gonadotropin receptors (Figure 1.1, adapted from Garcia-
Campayo and Boime 2001).  This has been accomplished by incorporating different β-
subunits within the same construct, such as FSHβ and hCGβ.  These “dual activity”  
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Figure 1.1 “Dual activity” gonadotropins.  Both LH and FSH β-subunits can be fused to the 
common α-subunit.  Association between the α-subunit and each individual β-subunit will occur 
and form a blend of functional FSH and LH proteins.  These proteins will bind and activate either 
the FSHR and or the LHR. 
 
gonadotropins have exhibited in vitro binding capacity to both FSH and LH receptors 
(Kanda et al. 1999; Garcia-Campayo and Boime 2001; Garcia-Campayo et al. 2004; 
Jablonka-Shariff et al. 2006), although variations in binding have been noted based on β-
subunit orientation (Garcia-Campayo and Boime 2001).  In sheep, an increase in estradiol 
production as a result of treatment with a dual active FSH/LH gonadotropin was similar 
to a combination of individual FSH and hCG hormones, suggesting the ability of the dual 
gonadotropin was sufficient to activate both receptors and elicit multiple biological 
responses (Adams and Boime 2008).  The ability to produce a single hormone that has 
both FSH and LH activity would simplify superovulation protocols and reduce costs 
associated with labor.  The optimal FSH:LH ratio during the follicular growth phase 
associated with superovulation is unclear (Donaldson and Ward 1986; Takagi et al. 2001; 
Kanitz et al. 2002), and, in human fertility, can be patient-dependent with factors such as 
age, parity, and overall ovarian function impacting results (Agostinetto 2009).  Supplying 
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a dual-active gonadotropin may alleviate some of the problems encountered with 
administering only FSH and allow the desired ratio of FSH:LH to be achieved using one 
molecule.  Further, the technology can be tweaked to include other gene domains such as 
angiogenic or steroidogenic factors (Adams and Boime 2008).   
Production methods  
The most common recombinant protein production method for hFSH is 
heterologous expression in Chinese hamster ovary (CHO) cells, a mammalian cell line 
that is capable of providing native post-translational modifications to nascent proteins.  
These cells can secrete the hormone into the culture media, from which it is purified and 
analyzed for activity.  Despite the fact that CHO cell cultures are able to produce proteins 
almost identical to their endogenous structure, these cells are cultured in vitro using fetal 
bovine serum (FBS), which could potentially harbor disease-transmissible materials.  The 
FBS that is routinely used in commercial production of recombinant gonadotropins is 
collected from countries that are free of prion diseases (to date) such as bovine 
spongiform encephalopathy (BSE) and variant Creutzfeldt-Jakob disease (vCJD).  
However, it can sometimes take years for symptoms to appear which makes this a fluid 
classification (Balen 2002).  CHO cells do not flourish properly in the absence of FBS, 
which makes harvesting adequate supplies of recombinant proteins from them difficult.  
Recently, recombinant gonadotropin production from modified CHO cells has been 
conducted in the absence of FBS, resulting in proteins that exhibit similar biological 
activity to previous products produced in the presence of FBS (Kim et al. 2010). 
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 Similar to hFSH, bovine (bFSH) was initially produced in CHO cells and found to 
have biological activity (Looney et al. 1988; Wilson et al. 1993), but is no longer 
available in sufficient quantities for commercial purposes.  Other production methods 
have been explored for both FSH and LH and have resulted in a biologically active 
protein.  However, none have proven superior to CHO cell production (except for not 
requiring FBS for cell culture).  These methods employ the use of bacteria (Wilson 
2009), viruses (Chappel et al. 1988), insects (van de Wiel et al. 1998; Ko et al. 2007; 
Zmora et al. 2007; Kazeto et al. 2008), tobacco plants (Dirnberger et al. 2001), yeast 
(Richard et al. 1998; Gadkari et al. 2003; Fidler et al. 2003; Kasuto and Levavi-Sivan 
2005), and transgenic milk (Galet et al. 2001; Coulibaly et al. 2002).  The use of hosts 
such as bacteria and yeast may provide a safer alternative to CHO production due to the 
lack of FBS utilization.  Conversely, these systems do not harbor the glycosylation 
capabilities employed by CHO cells, and in some cases hyperglycosylate proteins, which 
may or may not have positive effects on biological activity (Porro et al. 2005).  A 
chronological summary of the history of recombinant FSH and LH protein production 
schemes can be found in Tables 1.1 and 1.2, respectively.  These tables highlight the 
progression of recombinant gonadotropin production, as well as give insight into the 
protein construction and resulting activity of each construct.   
Delivery methods 
 In parallel with the quest for recombinant gonadotropins exhibiting longer in vivo 
biological half-life is an improved delivery method that would require fewer injections.  
Much research has been devoted to identifying an adjuvant that, when mixed with the  
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Table 1.1 Chronological history of recombinant FSH1 produced in heterologous systems. 
Species Production System In vitro activity In vivo activity Reference 
Bovine BPVa Progesterone in granulosa cells Activity in SP Assay Chappel et al. 1988 
 CHO cellsa NR Increased embryos in cattle Looney et al. 1988 
Human CHO cellsa Aromatase in rat granulosa cells NR Keene et al. 1989 
Human CHO cellsf Estrogen in granulosa cells Increased FSH activity with CTP Fares et al. 1992 
Bovine CHO cellsa NR Increased embryos in cattle Wilson et al. 1993 
Human CHO cellsb pI and isoform heterogeneity like 
native 
NR Olijve et al. 1996 
Porcine Insecta Estrogen in Sertoli cell assay Mouse uterine weight assay Inaba et al. 1997 
Rat CHO cellsb Active in Sertoli and granulosa cells Activity in SP Assay Hakola et al. 1997b 
Bovine Baculovirusa cAMP NR Van de Wiel et al. 1998 
Ovine Yeastc cAMP from CHO cells NR Fidler et al. 1998 
Porcine Insecta Progesterone in granulosa cells NR Kato et al. 1998 
 Yeastc cAMP in CHO cells; progesterone 
in Y1 adrenal cells 
NR Richard et al. 1998 
Human CHO cellsa Y1 adrenal and CHO cells 
stimulated 
Activity in SP Assay D’Antonio et al. 1999 
Bovine Tobacco plantc cAMP in CHO cells Increased oocytes Dirnberger et al. 2001 
Human CHO cells NR Stimulated follicles in cattle Takagi et al. 2001 
Bovine Rabbit milkb Luciferase in CHO cells NR Coulibaly et al. 2002 
Ovine Yeastc cAMP from CHO cells NR Fidler et al. 2003 
Human NR NR Human IVF Devroey et al. 2004 
Channel 
catfish 
Drosophilaa cAMP in COS cells; steroidogenesis 
in ovarian and testicular cells 
NR Zmora et al. 2007 
Human Transgenic 
micec 
cAMP production by CHO cells NR Kim et al. 2007 
Manchurian 
trout 
Silkwormc cAMP from COS cells Increased follicular diameter in 
female adult trout ovary 
Ko et al. 2007 
Human CHO cellsd NR Increased estrogen production in 
sheep 
Lemke et al. 2008 
7 
Species Production System In vitro activity In vivo activity Reference 
Japanese 
eel 
Drosophilaa cAMP production by COS cells Failed to stimulate gonadal growth 
in immature male eels 
Kazeto et al. 2008 
Bovine Bacteriac NR Activity in SP Assay Wilson 2009 
Equine CHO cellsd NR Increased total number of follicles Jennings et al. 2009 
 CHO cellsb cAMP in CHO cells Activity in SP Assay Fachal et al. 2010 
Human CHO cellsg NR Hyperglycosylation increased 
fertility rates 
Trousdale et al. 2009 
Japanese 
eel 
Silkwormd Eel oocyte maturation Induced spermatogenesis in 
immature eels 
Kobayashi et al. 2010 
1Abbreviations: FSH: follicle stimulating hormone, BPV: Bovine Papilloma Virus, SP: Steelman-Pohley assay, NR: not reported, cAMP: 
cyclic adenosine monophosphate, CHO: Chinese hamster ovary, CTP: carboxy terminal peptide. aIndividual subunits assembled post-
production, bfused protein α/β orientation, cfused protein β/α orientation, dfused protein β-CTP-α, efused protein α-CTP-β, findividual 
subunits assembled post-production with β-CTP, gFSH construct hyperglycosylated. 
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Table 1.2 Chronological history of recombinant LH1 produced in heterologous systems. 
Species Production System In vitro activity In vivo activity Reference 
Bovine CHO cellsa Increased progesterone in ovine luteal 
cells 
NR Kaetzel et al. 1985 
Rat CHO cellsb Increase cAMP in mouse Leydig cells No seminal vesicle increase in rats Hakola et al. 1997a 
Equine 
 
Rabbit milkc Increased testosterone in rat Leydig 
cells 
No significant ovarian weight 
increase when compared to 
controls 
Galet et al. 2001 
Human Yeasta Increased progesterone in Leydig cells NR Gadkari et al. 2003 
Equine Insecta Increased progesterone in Y1 adrenal 
cells 
No effect on ovary growth of rats Legardinier et al. 2005 
Tilapia Yeastc Increased testosterone in tilapia testes NR Kasuto and Levavi-
Sivan 2005 
Channel 
catfish 
Drosophilaa Stimulated cAMP in COS cells; 
induced steroidogenesis in ovarian and 
testicular cells 
NR Zmora et al. 2007 
Equine CHO cellsc Increased testosterone in equine Leydig 
cells 
Increased LH and testosterone in 
stallions 
Jablonka-Shariff et al. 
2007 
Manchurian 
trout 
Silkwormc cAMP increased in COS cells No effects on female adult trout 
ovary 
Ko et al. 2007 
Bovine CHO cellsde Increased progesterone in rat granulosa 
cells and bovine theca cells (α-CTP-β.> 
β-CTP-α) 
NR Grinberg et al. 2008 
Japanese Eel Drosophilaa cAMP increased in COS cells Failed to stimulate gonadal growth 
in immature male eels 
Kazeto et al. 2008 
 Silkwormd Induced eel oocyte maturation Induced spermatogenesis in 
immature eels 
Kobayashi et al. 2010 
1Abbreviations: LH: luteinizing hormone, CHO: Chinese hamster ovary, NR: not reported, cAMP: cyclic adenosine monophosphate, CTP: 
carboxy terminal peptide. aindividual subunits assembled post-production, bfused protein α/β orientation, cfused protein β/α orientation, 
dfused protein β-CTP-α, efused protein α-CTP-β.
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gonadotropin, would allow a slow release of FSH over time to induce a superovulatory 
response similar to multiple traditional injections (Takedomi et al. 1995; Satoh et al. 
1996).  Looney et al. (1981) injected cattle once a day with FSH embedded within gelatin 
and found the single injection per day resulted in more corpora lutea and viable embryos 
when compared to the standard protocol of twice a day injections.  FSH is rapidly cleared 
from circulation, being undetectable in plasma 12 hours after intra-muscular injection.  
However, after intra-muscular injection of FSH dissolved in aluminum hydroxide gel into 
cattle, FSH was detected in plasma up to 4 days post-injection, negating the need for 
multiple injections (Kimura et al. 2007).  In another study, Floyd (2007) tested the ability 
of polyethylene glycol (PEG) or polyacrylamide to act as a slow-release implant for FSH 
in vitro; results indicated both materials enhanced slow release of FSH over a 24 hour 
period.  Porcine FSH bound to PEG is competent in receptor activation in vitro and also 
reduces immunological response without affecting bioactivity in vivo, but more studies 
are necessary to determine the effect on half-life sustainability (Uchiyama et al. 2010).  
Low et al. (2005) demonstrated that FSH bound to the Fc domain of IgG retained in vivo 
activity after transport across gut epithelial cells, introducing the possibility for an oral 
administration route.  hFSH has also been administered through less frequent vaginal 
subcutaneous injections which provoked an adequate superovulatory response while 
using a minimal amount of hormone given with fewer required injections (Hsu et al. 
2009).    
Superovulation  
10 
 Superovulation is the manipulation of the endogenous FSH surge that gives rise to 
a follicular wave that can be persuaded to produce multiple follicles capable of ovulating.  
Superovulation, along with embryo transfer, is used to propagate superior genetics 
horizontally within a single generation.  Once multiple follicles have ovulated, the ova 
can be fertilized with fresh or frozen semen and after 7 days, the embryos are collected 
by non-surgically washing via uterine lavage, a technique called flushing.  The embryos 
are then transferred to recipient dams, a process termed embryo transfer. 
Occurrence 
Bovine superovulation is becoming more common, as indicated by the increasing 
number of embryo collections and subsequent transferable embryos.  The International 
Embryo Society Data Retrieval Committee reported in 2007 over 122,000 bovine embryo 
collections spanning 5 continents (52% of the total embryos transferred reported from 
North America), resulting in almost 764,000 transferable embryos for an average of ~6 
embryos/collection (Thibier 2008).  This activity has nearly doubled in 10 years, from 
~82,000 embryo collections and ~456,000 transferable embryos recorded in 1997, 
however the average of ~6 embryos/collection has not changed.  Worldwide, the use of 
embryo transfer in other ruminant species (namely sheep, goats, and deer) has also 
increased, with ~10,000 embryo collections in 1997 as compared to ~27,000 embryo 
collections in 2008 (Thibier 1998; Thibier 2008).  At the onset of superovulatory 
protocols in the 1970s, >95% of all recovered embryos were collected within the dairy 
industry and were transferred surgically.  After non-surgical collection and transfer 
techniques were developed, the use of superovulation expanded to the beef industry 
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where it is currently responsible for ~70% of all the recovered embryos.  Despite the 
steady increase in occurrence of superovulation, transferable embryo recovery 
efficiencies have been stagnant at ~6 recovered embryos per collection (Thibier 1998; 
Hasler 2003; Thibier 2008).  
Optimization of FSH use in superovulation 
 There have been many advances in the use of FSH in superovulatory protocols 
where the desired outcome is to maximize the height and breadth of the endogenous FSH 
curve to increase the number of follicles in several size categories as well as the number 
of ovulations (Gibbons et al. 1997).  Many aspects have been considered including the 
timing of exogenous FSH delivery relative to follicular wave emergence (Adams et al. 
1992; Nasser et al. 1993; Ginther et al. 1996), methods of FSH delivery (Looney et al. 
1981; Murphy et al. 1998; Bo et al. 1994), location or route of delivery (Bo et al. 1994; 
Mapletoft et al. 2002), and the purity of the FSH being delivered (Hill et al. 1984; 
Donaldson and Ward 1986; Braileanu et al. 1998).   
Ovarian follicles grow in waves (2 or 3 in the bovine estrous cycle) culminating in 
one follicle gaining dominance and regression of the remaining follicles (Adams et al. 
1992).  A new follicular wave is initiated following the demise of the dominant follicle 
(Ko et al. 1991; Adams et al. 1993).  Destruction of the dominant follicle is a proven 
method of initiating a new follicular wave and can be performed mechanically with 
transvaginal ultrasound-guided follicular ablation (Bergfelt et al. 1994; Bodensteiner et 
al. 1996; Bergfelt et al. 1997; Baracaldo et al. 2000).  This may not be useful in a 
commercial livestock setting due to high labor costs.  Removal of the dominant follicle 
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can also be achieved by various pharmaceutical treatments (Bo et al. 1994; Bo et al. 
1996; Mapletoft et al. 2002; Bo et al. 2008).   
Typical superovulatory protocol in cattle  
A natural follicular wave (usually the second) is enhanced by initiation of FSH on 
the day of or the day before the start of the new follicular wave when the largest follicles 
of the new wave average ~4 mm, approximately day 10 following estrus.  FSH is 
delivered in a regimen of 8 total intramuscular injections, twice daily in decreasing doses 
over 4 days (25-50 mg total protein delivered, dependent upon breed, parity, age, weight, 
etc.).  ProstaglandinF2α (25 mg/dose) is usually administered concomitant with the 5th 
and 6th FSH injection, approximately 48 and 36 hours before expected estrus (Bo et al. 
1995; Mapletoft et al. 2002).  Cows are bred by artificial insemination at standing estrus 
and 12 hours later.  Seven days later, embryos are collected by non-surgical trans-cervical 
uterine lavage, processed, graded, and transferred fresh or frozen for later use. 
Challenges within the current bovine superovulation system 
 Bovine ovarian hyperstimulation is an essential step in the maintenance of high 
quality genetics in the beef and dairy industries.  Currently, bovine ovarian 
hyperstimulation (or superovulation) requires pituitary-derived FSH, typically obtained 
from porcine or ovine species, to stimulate multiple follicles to achieve dominance and 
ovulatory capacity.  In the past, products such as equine chorionic gonadotropin (eCG), 
also known as pregnant mare serum gonadotropin (PMSG), have been used to stimulate 
superovulation.  The use of FSH has advantages over eCG that include a decrease in 
follicular cysts and more consistent results; however, FSH has a shorter half-life than 
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eCG (~1.5 h vs. ~120 h, respectively) requiring multiple injections to obtain results 
similar to those found with eCG (Galli et al. 2003).  Studies have shown FSH yields a 
more consistent ovulatory response (Bellows and Short 1972; Elsden et al. 1978).  
Further, the prolonged biological activity of eCG can negatively affect early embryonic 
development, requiring the use of an anti-eCG injection to reduce activity (Boland et al. 
1991).  Irrespective of the gonadotropin choice, the most labor-intensive and costly part 
of superovulation is the administration of gonadotropins.  With increasing labor costs, the 
embryo transfer industry will likely become stagnant without improvements (Hasler 
2003).   
Multiple factors have confounded efforts to standardize superovulatory protocols 
in cattle.  Superovulatory variation has been reported at a range of 0-60 recovered 
embryos per donor, with 20% of donors producing no transferable embryos (Hasler 
2003).  Aged donors have been found to exhibit a lower follicular and ovulatory response 
as a result of ovarian hyperstimulation (Malhi et al. 2008), and differences in breed-
specific responsiveness have been debated (Donaldson 1984; Krininger et al. 2003).  A 
large source of variation comes from the individual farm, encompassing environmental 
location, recipient and/or donor management, semen/embryo handling, and animal 
nutrition schemes (Kafi and McGowan 1997; Yaakub et al. 1999; Stroud and Hasler 
2006).    
Another source of variation in superovulatory response may result from the 
presence of a dominant follicle.  Guilbault et al. (1991) reported a lower number of 
corpora lutea and lower progesterone concentrations in heifers superovulated in the 
14 
presence of a dominant follicle when compared to those without a dominant follicle, 
suggesting a reduced superovulatory response.  Other research supports these results, 
finding an increased number of transferable embryos following follicular ablation (Kim 
et al. 2001; Lima et al. 2007).  Stock et al. (1996) found that when a dominant follicle 
was present, follicular response to superovulation was not hindered, but fewer ovulations 
occurred.  Diaz et al. (2001) reported reduced follicular response in the presence of a 
dominant follicle, but suggested exogenous FSH may compensate for any deleterious 
effects resulting from the dominant follicle.  In a conflicting study, no negative effects 
were reported on superovulatory response of lactating dairy cows with a dominant follicle 
(Maciel et al. 1995).  All of these issues potentially contribute to bovine superovulatory 
variability and lead to reduced embryo recovery rates, usually requiring specialization of 
the protocol (Lerner et al. 1986).  
Superovulatory response variability introduced by gonadotropins 
One of the primary contributing factors to low embryo recoveries is the variability 
introduced by pituitary-derived gonadotropins which suffer from the following 
drawbacks: 1) potentially high FSH:LH ratios (Kafi and McGowan 1997; Galli et al. 
2003; Adams and Boime 2008), 2) batch-to-batch inconsistencies (Murphy et al. 1984; 
Kanitz et al. 2002; Galli et al. 2003), and 3) potential disease transmission (Galli et al. 
2003; Adams and Boime 2008). 
 Variable LH activity within commercially-available pituitary-derived preparations 
of FSH is a clear disadvantage to the use of these products.  Failure to limit LH 
contamination in FSH preparations reduces the percentage of transferable embryos and 
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increases variability of successful transfers (Ward 1986; Kanitz et al. 2002).  An 
increased amount of LH early in the superovulatory protocol may activate the LH 
receptor (LHR) leading to premature luteinization, resulting in early ovulation of the 
follicles and ultimately leading to decreased fertilization rates and embryo production.  
Further, the concentration of naturally-occurring isoforms of LH present within the FSH 
preparation may interfere with the effectiveness of FSH.  Kanitz et al. (2002) 
demonstrated that LH was unnecessary for efficient superovulation and that a small 
amount was tolerable to the protocol before it began to have a negative effect on 
fertilization rates and the number of transferable embryos.  Other researchers have 
supported this hypothesis and suggest a “ceiling effect” occurs where limited 
concentrations of LH can be tolerated during folliculogenesis before it manifests 
deleterious effects (Loumaye 2002; Muasher et al. 2006; Gibreel and Bhattacharya 2010).  
The number of recovered transferable embryos and the amount of LH detectable in FSH 
preparations have an inverse relationship (Chupin et al. 1984; Donaldson and Ward 1986; 
Donaldson et al. 1986; da Costa et al. 2001).  Recent commercially available FSH 
preparations contain a reduced amount of detectable LH activity (achieved through 
biochemical purification methods), and increasing the dosage up to twofold above the 
conventional pituitary-derived FSH dose for superovulation does not appear to affect 
embryo quality (Gonzalez et al. 1990).  
Studies have been performed to identify a range of acceptable LH contamination.  
Willmott et al. (1990) suggests the acceptable maximum of detectable LH activity of an 
FSH preparation to be between 15 and 20% before superovulatory response is hindered.  
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Tribulo et al. (1991) reports a similar optimal LH amount (~16% of the preparation), 
however seasonal affects on superovulatory response were noted.  Seasonal affects were 
also noted by Page et al. (1989), where LH contamination had no effect on 
superovulation of Holstein heifers in cool months, but a small amount of LH was 
preferable during the stressful heat of summer months.  Takagi et al. (2001) demonstrated 
that heifers superovulated with a recombinant hFSH preparation (no detectable LH) had 
reduced follicular maturation, which they attributed to the lack of LH in the preparation.   
 The amount of LH in an FSH preparation may influence the dosages of FSH 
required because the granulosa cells of the larger follicles are predominantly LH-
dependent, rather than relying solely on FSH to mature to ovulation (Adams et al. 1992).  
This fact is crucial to our proposed working model, where low to no detectable LH is 
included in the early FSH injections of superovulation, followed by an increasing 
percentage of LH in the later stages, which may result in more ovulations, providing the 
opportunity for increased fertilization (Figure 1.2).  This could be accomplished by 
combining pure, recombinant preparations of each protein in a fixed and controllable 
ratio.  Alper et al. (2008) reported that combining FSH and LH into one dose and treating 
rats did not affect either of the proteins’ bioactivity.  Unfortunately, the precise ratio of 
FSH:LH at various times during superovulation is unknown, but recombinant protein 
production is enabling technology to further define the role of each gonadotropin in the 
endocrine-intrafollicular relationship during a superovulatory situation.  Experimentation 
with pure gonadotropins is necessary to elucidate these issues, and recombinant protein is 
the most efficient way to manufacture preparations that are completely void of the 
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Figure 1.2 Working model for future superovulation regimen utilizing pure, recombinant 
FSH and LH preparations and corresponding ovarian and follicular responses beginning on 
day 10 of estrous cycle. 
A: Relative doses of recombinant FSH and LH administered in a single injection during a typical 
4 day dose regimen for superovulation (days 10-14 of estrous cycle).  Superovulatory doses for 
FSH begin at a high level (indicated by dark grey) and taper off to a low level (indicated by the 
fade gradient ending in white).  Doses for LH begin at a low level (indicated by white) at the 
beginning of superovulation and increase throughout dosing regimen, ending at a high level to 
induce ovulation of multiple follicles (indicated by gradient ending in dark grey).  B: Cohort of 
follicles maturing during superovulation.  Deviation occurs when follicles reach ~10 mm, 
approximately on Day 3 of superovulation.  The follicles that fail to attain a diameter of ~10 mm 
usually become atretic while the deviated follicles will go on to ovulation.  C: GC of DF 
predominantly express FSHR (7-pass transmembrane protein with dark grey bars) with a limited 
amount of LHR (7-pass transmembrane protein with light grey bars) on their surface until 
deviation, in which they alter expression to predominantly LHR to prepare for ovulation. D: GC 
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of SF also predominantly express FSHR prior to deviation, however following deviation, they 
become atretic and do not express significant quantities of FSHR or LHR, and the receptors that 
may be present on the cell surface are inactivated due to the presence of the DF (*).  
Abbreviations: SO: superovulation, E: estrus, OV: ovulation, rec: recombinant, FSH: follicle 
stimulating hormone, LH: luteinizing hormone, GC: granulosa cell, DF: dominant follicle, SF: 
subordinate follicle, FSHR: FSH receptor, LHR: LH receptor. 
 
contaminating gonadotropin.  Further, experimenting with the delivery method (mini-
pump or implant, for example) of the gonadotropins, specifically LH, could alleviate 
some of the disadvantages of using the product, namely premature ovulation of maturing 
follicles resulting from the delivered bolus.  
Because ~60 isoforms of FSH and LH are naturally produced within the pituitary 
(based on phase of estrous cycle as well as age and parity), differences exist within and 
among batches of pituitary extracts (Kanitz et al. 2002; Gibreel and Bhattacharya 2010).  
Gonadotropin isoforms differ based on their degree of glycosylation, as well as the 
specific carbohydrate moieties that are incorporated (Stanton et al. 1993; D'Antonio et al. 
1999).  Phillips et al. (1993) tested five pituitary preparations for in vitro activity and 
metabolic clearance rates (using a rodent model), and found there were differences 
among the batches for both assays.  Kanitz et al. (2002) tested four pituitary batches of 
FSH for bioactivity using a rat ovarian weight gain assay, followed by testing 
superovulatory responses in cattle.  Their findings showed a wide range of bioactivity and 
the resulting number of transferable embryos differed among the preparations.     
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A more recent concern is the potential for pituitary extracts to harbor infectious 
agents, including prions, which may be passed to the recipient animal (Galli et al. 2003; 
Adams and Boime 2008).  Some European countries have banned the use of pituitary-
derived gonadotropins in superovulation because of this risk, disabling the current 
protocols and crippling the embryo transfer industry in those countries.  One possible 
solution is to use recombinant gonadotropins, which is well established for human in 
vitro fertilization protocols (Galli et al. 2003).  
Costs associated with superovulation 
 Currently, gonadotropins are the most expensive component of the superovulation 
protocol, costing ~$100/superovulation to meet the requirements for FSH using a 
pituitary-derived product.  Introducing recombinant FSH into this protocol may not 
substantially reduce cost, but the benefits of using a pituitary-free product (no pituitary 
contaminants, no possibility for disease transmission, increased transferable embryo 
recovery rates, etc.) would likely yield considerable benefits.  The cost of producing 
recombinant proteins from a small culture in a university setting can be as much as 3-5X 
higher than that of the pituitary product; however, industrializing the production will 
substantially reduce costs incurred due to culture media and labor, the primary 
contributing factors to the expense. 
Use of LH in synchronizing ovulation in cattle 
 A combination of progesterone and estrogen is the conventional follicular wave 
synchronizing protocol which will initiate a follicular wave 4 days post-treatment (Bo et 
al. 1995).  Recently, research has focused on alternative synchronizing methods, such as 
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follicular ablation, gonadotropin releasing hormone (GnRH), or LH.  As previously 
mentioned, follicular ablation may not be cost-effective in farm settings, as it requires 
expensive technology that must be operated by skilled professionals (Bo et al. 2010).  
GnRH is the conventional ovulatory stimulator in synchronization protocols (Pursley et 
al. 1995), but has been shown to be less effective than pituitary LH at stimulating 
ovulation (56% and 78%, respectively) in dairy heifers, however both products induced a 
new follicular wave within 2 days post-treatment if that treatment resulted in ovulation 
(Martinez et al. 1999).  Ambrose et al. (2005) reported pregnancy rates of 59% when 
synchronizing estrus with GnRH [combined with timed artificial insemination (AI)] as 
compared to 46% with the use of pituitary LH, but also indicated an increase in 
progesterone production after LH treatment.  Further, the cost-effectiveness of LH as an 
ovulatory stimulator (when compared to GnRH) is currently unknown (Ree et al. 2009).  
A combination of the two products has shown more promising results than using two 
treatments of GnRH in a timed AI scenario (Pursley et al. 1995; Colazo et al. 2009).  
Neither GnRH nor LH have historically proven to elicit reliable and predictable 
ovulations possibly due to efficacy differences during various stages of cyclicity leading 
to premature ovulations in some animals (Martinez et al. 1999); thus, a carefully 
characterized recombinant LH product may overcome these issues and allow for more 
dependable ovulations and synchronizations.  
Human infertility 
 Gonadotropins have been used to combat human infertility since the early 1930s.  
After the discovery of the pituitary gonadotropins and their actions, researchers began 
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harvesting animal pituitaries (mainly sheep and pigs) to administer the extracts 
containing the gonadotropins to infertile women.  Upon discovering disease transmission 
that was linked to pituitary preparations, coupled with the production of antibodies as a 
result of repeated injections of animal pituitary extract into women, urinary 
gonadotropins began to be used instead (Lunenfeld 2004; Gibreel and Bhattacharya 
2010).  Gonadotropins are found in high quantities in the urine of post-menopausal 
women due to the lack of estrogen production.  A reduction in estrogen leads to an 
increase in GnRH and subsequently more FSH and LH, which is eliminated through the 
urine.  Since the 1950s (when urine preparations were first used), many purification 
techniques have been implemented and recently, only subjects from countries without 
endemic prion disease in cows or humans are allowed to donate urine (Balen 2002).  
Unfortunately, urinary-derived gonadotropins still harbor many impurities even after 
multiple stages of purification (Bassett et al. 2009).  A discovery of prion proteins in 
urine samples from multiple animals, including humans, confirmed a need for safer 
infertility treatments (Balen 2002; Lunenfeld 2004).   
 In the 1990s, recombinant preparations were implemented for human infertility 
protocols, and researchers have since been attempting to make the safest, most efficient 
recombinant gonadotropins possible.  Many clinical trials have suggested that urinary 
preparations are more reproductively efficient (Muasher et al. 2006; Gibreel and 
Bhattacharya 2010) and more cost effective (Balasch and Barri 2001) than recombinant 
preparations.  There is opposing research suggesting that recombinant proteins are more 
effective in terms of pregnancy rates (Balasch and Barri 2001) and the disease-harboring 
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potential of the urinary preparations limits their use (Matorras and Rodriguez-Escudero 
2002; Reichl et al. 2002).  A ban on urinary gonadotropin preparations is in effect in 
some European countries (similar to that placed on pituitary extracts), which validates the 
cautionary use of urinary-derived gonadotropins.  The difficulty in regulating and 
monitoring the ~6000 donors that are necessary to fulfill the need for urinary-derived 
gonadotropins each year (a level which will surely rise with increased demand), and the 
fact that there are no minimum qualifications for donors, suggest and increased value for 
recombinant proteins (Lunenfeld 2004).    
 The protocol for ovarian stimulation in humans begins with pharmacological 
pituitary suppression using GnRH agonists or antagonists, allowing native production of 
gonadotropins to increase.  The endogenous production is supplemented by exogenous 
hCG or recombinant FSH and/or LH allowing the ovary to be hyperstimulated, resulting 
in a larger number of follicles to be collected.  The oocytes are then surgically retrieved 
and cultured until fertilization in vitro, resulting in embryo(s) that are placed into a 
hospitable uterus for implantation and term pregnancy (Pauli et al. 2009).    
Gonadotropin Background 
FSH and LH are heterodimeric glycoprotein hormones consisting of an α- and β-
subunit produced from the gonadotroph cells in the anterior pituitary gland.  These 
proteins, along with the other proteins within this family such as thyroid stimulating 
hormone (TSH) and hCG (of placental origin), are the products of two separate genes.  
The gene products are noncovalently associated after translation.  The α-subunits within 
this family are highly conserved amongst mammalian species, whereas the β-subunit 
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confers specificity of receptor binding and are therefore distinct (Pierce and Parsons 
1981).  
Protein structure 
The FSH and LH subunits contain disulfide bridges: 5 within the α-subunit and 6 
within the β-subunit (Pierce and Parsons 1981; Furuhashi et al. 1994).  Furuhashi et al. 
(1994) demonstrated that when certain disulfide bonds were disrupted within the α 
subunit, protein activity was lost by reducing secretion and/or increasing degradation, 
while disrupting other disulfide bonds had no consequence on subunit interaction or 
protein activity.  It has also been suggested that despite disruption of one disulfide bond, 
tertiary structure can be maintained; however, after two or more bonds are disrupted, 
protein activity is lost, suggesting subunit and/or dimer structure had been compromised 
(Giudice and Pierce 1979).  
These glycoprotein hormones are stabilized by a cysteine knot formed by three 
disulfide bridges in the center of the protein which creates large loops out of each subunit 
(Xing et al. 2004a).  Further stabilizing the FSH structure is a loop formed from the β-
subunit around the α-subunit like a “seat-belt,” and a second smaller loop formed by the 
β-subunit, both thought to be crucial for accurate receptor binding (Simoni et al. 1997; 
Rose et al. 2000).  The “seat-belt” region forms a hole within the β-subunit which houses 
a glycosylated loop on the α-subunit, stabilizing the molecule even further (Xing et al. 
2004a). 
Post-translational modifications 
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The primary reason recombinant gonadotropin production has been limited is a 
result of the inability to effectively recreate post-translational modifications (namely 
glycosylations) in certain heterologous systems.  Both FSH and LH are post-
translationally glycosylated.  There are two complex N-linked glycosylation sites on the 
common α-subunit (N56 and N82) and two or one N-linked glycosylation sites on the 
FSH (N13 and N30) and LH (N13) β-subunit, respectively (Pierce and Parsons 1981; 
Wilson et al. 1990).  As previously mentioned, in addition to the two N-linked 
glycosylations, there is a unique ~25 amino acid domain on the placental-derived hCG β-
subunit (Residues 122-146) called the CTP which is serine and proline rich, coding for 
four O-linked glycosylation sites (Pierce and Parsons 1981).  
As a consequence of different trimming and extension, the carbohydrates added to 
FSH and LH are heterogeneous.  These variations make up the ~20 FSH isoforms and 
~39 LH isoforms that are produced in vivo depending on phase of estrous cycle as well as 
age, sex, and parity of contributing animals (Stanton et al. 1993; D'Antonio et al. 1999; 
Gibreel and Bhattacharya 2010).  While FSH is more likely to include sialic acid 
additions, LH is more likely to have sulfate groups incorporated into these glycosylations.  
In fact, there are no known isoforms of LH that incorporate sialic acid residues (Green 
and Baenziger 1988).  Another carbohydrate frequently added to gonadotropins is 
galactose.  The carbohydrates are incorporated in varying configurations resulting in di- 
or tri-branched structures providing a net negative charge to the protein (Green and 
Baenziger 1988; Ulloa-Aguirre and Timossi 1998).   
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Conventionally, glycosylations have been thought to increase biological activity 
by protecting the core protein structure from proteases within the bloodstream of 
mammals and reducing kidney and liver clearance (Morell et al. 1971; Sinclair and Elliott 
2005).  Fiete et al. (1991) discovered a receptor on liver endothelial cells that recognized 
and bound the mannose residues found on the sulfonated side chains of human LH and 
FSH (which are similar to those found on the bovine homolog), presumably allowing 
isoforms with a higher degree of sulfonation to be cleared at a faster rate resulting in a 
reduced biological activity (Wide et al. 2009).  The specific amino acid residues 
exhibiting the sulfonated glycosylation (Roseman and Baenziger 2000) and the sialylated 
glycosylation (Bishop et al. 1994) may also be important in the recognition and disposal 
of LH and FSH, respectively.  
In addition, glycosylation increases solubility and stability of proteins, facilitates 
proper protein folding, association with other subunits, appropriate charge, disulfide 
bridge formation (Rose et al. 2000), and enzyme kinetics (Shental-Bechor and Levy 
2009).  The reason for these consequences is unclear, but the addition of sialic acid to the 
nascent protein may be important as sialic acid is thought to increase half-life due to the 
hydrophilic nature of the molecule, allowing it to maintain increased solubility in the 
blood (Sinclair and Elliott 2005).  FSH isoforms with higher sialic acid content have been 
found to have an increased bioactivity, likely due to reduced clearance through the kidney 
and liver (D'Antonio et al. 1999; Perlman et al. 2003).  LH is not sialylated (Green and 
Baenziger 1988), suggesting it’s half-life may not be as important for its function as a 
result of the release patterns of LH versus FSH.  FSH needs to be supplied continually to 
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the cohort of follicles during the pre-deviation period for adequate maturation, suggesting 
a longer bioactivity would be necessary (achieved by more glycosylations and the 
addition of sialic acid), whereas LH only needs to function for a brief period based on the 
length of the pre-ovulatory surge.  Half-life may be inconsequential if the delivery 
method can supply the gonadotropin to its target area before it can be broken down by 
proteases, allowing for optimal bioactivity.  Glycosylations may not be as important if a 
steady supply of hormone initiates adequate receptor and intracellular response (Barrios-
De-Tomasi et al. 2002). 
Subunit assembly 
It appears that as the individual subunits pass through the glycosylation apparati, 
they become non-covalently associated within the endoplasmic reticulum, after the initial 
glycosylations are added, and the disulfide bonds have been generated.  A loop on the α-
subunit which contains a glycosylation (residues 33-58) is “threaded” through a loop 
within the β-subunit produced by the “seat-belt” region, and one of the disulfide bonds 
(Xing et al. 2004a).  As this “threading” is occurring, the latter disulfide bond is broken 
and re-established after the α-subunit has positioned itself under the “seat-belt”, 
subsequently allowing only harsh reducing agents to cause disassociation (Xing et al. 
2004b).  Along with the disulfide bonds, the aforementioned loop on the α-subunit 
(termed the “long loop”) is also important in this association, based on mutagenesis 
studies performed by Liu and Dias (1996) who demonstrated a loss of heterodimer when 
a certain residue series was disrupted.     
Gonadotropin function 
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FSH is responsible for growth and maturation of multiple subordinate follicles 
during a follicular wave within the ovary via granulosa cells in the female and facilitating 
spermatogenesis by Sertoli cells in the male (Pierce and Parsons 1981; Wilson et al. 
1990; Rose et al. 2000).  LH is the trigger for ovulation of the dominant follicle(s) in 
females and is responsible for release of testosterone from the Leydig cells of males 
(Pierce and Parsons 1981; Simoni et al. 1999).  FSH induces the aromatization of 
androgens (supplied by the interstitial and theca cells) in the granulosa and Sertoli cells, 
resulting in estrogen synthesis.  LH triggers the synthesis of androgens such as 
testosterone (Hillier et al. 1994).      
Gonadotropin regulation at the neural level 
 FSH and LH respond to oscillations in expression of GnRH in the hypothalamus 
through the action of the hypothalamic-pituitary axis.  GnRH is released in a pulsatile 
fashion from the hypothalamus which triggers an increase in expression and production 
of LH and, to a smaller extent, FSH (Clarke and Pompolo 2005).  The mechanism by 
which GnRH stimulates transcription of the appropriate gonadotropin is not well 
understood, but a number of possible intracellular signal pathways are activated by the 
ligand-bound GnRH receptor (Thackray et al. 2010).  The differential up-regulation of 
specific gonadotropins could also be due to the frequency or amplitude of the pulses of 
GnRH (Melamed 2010). 
 FSH and LH have been detected in fetal samples, suggesting the presence of 
operational GnRH (Plant 2002; Delemarre et al. 2008); however, birth levels of FSH and 
LH are undetectable and do not return until the onset of puberty.  For this reason, puberty 
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is defined as the “reactivation” of GnRH which first stimulates an increase of LH pulses 
solely at night followed by the onset of a regular pulsatile pattern (Ebling 2005; 
Delemarre et al. 2008).  During the pre-pubertal period, levels of GnRH mRNA have 
been measured at adult levels, but either an inhibitor prevents the protein from 
functioning within the hypothalamus (gamma aminobutyric acid and neuropeptide Y are 
potential candidates), or a stimulus has been taken away that was present during gestation 
(kisspeptin receptor possibly; Plant 2002; Ojeda et al. 2006).  Once puberty is 
established, kisspeptin protein and receptor are detected within the hypothalamus which 
is thought to stimulate GnRH release, subsequently resuming the episodic releases of 
FSH and LH (Navarro et al. 2005; Roseweir and Millar 2009).    
Inhibins, activins and follistatins are dimerized peptides produced primarily from 
ovarian structures that have been shown to regulate the production of FSH and, to a lesser 
extent, LH (Dupont et al. 2003; Thackray et al. 2010).  Inhibin participates in a negative 
feedback relationship with FSH.  As more inhibin is produced, less FSH is produced from 
the anterior pituitary because of antagonistic effects on the activin gonadotroph receptor, 
rendering it useless (Rivier et al. 1986).  Activin and follistatin work together in an 
autocrine or paracrine fashion to regulate the expression of FSH β-subunit.  Activin 
directly up-regulates expression and follistatin binds activin to prevent FSHβ up-
regulation through activin receptor activation (Dupont et al. 2003; Bilezikjian et al. 2004; 
Melamed et al. 2006).  
Gonadotropin regulation at the ovarian level  
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Cattle tend to have 2 or 3 follicular waves per estrous cycle (Adams et al. 1992; 
Ginther et al. 1996), during which FSH is critical to the growth of the cohort of 
subordinate follicles (Pierce and Parsons 1981).  During the last follicular wave, one 
follicle is set apart to become dominant (in a process termed divergence) and will 
continue to ovulation while the remaining subordinate follicles become atretic and 
regress (Ginther et al. 1996).  Once the dominant follicle (DF) has been established and 
as it advances towards ovulation, its dependence upon FSH is diminished due to the 
increased expression of LH surface receptors on the granulosa cells and the decreased 
expression of FSH receptors.  At this time, FSH becomes unnecessary due to the newly 
established reliance upon LH.  Once the DF is established, it begins to produce inhibin 
(Adams et al. 1992) and the subordinate follicles become less responsive to FSH as well 
(Simoni et al. 1997).  The subordinates also begin producing more estrogen, a negative 
regulator of FSH (Thackray et al. 2010), due to the aromatization of androgens facilitated 
by the newly established LH surface receptors (Richards and Hedin 1988; Ginther et al. 
1996).  Along with the up-regulation of LH receptors in the granulosa cells, estrogen 
triggers the up-regulation of LH receptors on theca cells within the ovary (Richards and 
Hedin 1988; Ginther et al. 1996).  The increased expression of LH receptors prepares the 
DF for an LH surge which culminates in ovulation (Dufau 1998).  
Glycoprotein Hormone Receptor 
 The receptor for this class of peptide hormones is a G-protein coupled 7-pass 
transmembrane receptor consisting of three domains: extracellular, transmembrane, and 
C-terminal.  There are marked differences between the FSH receptor (FSHR) and LH 
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receptor (LHR), most being seen in the extracellular and C-terminal domains.  The 
extracellular domain is made of repeated motifs of about 24 residues called leucine-rich 
repeats (LRR) that are important for protein-protein interactions, protein-receptor 
binding, and cell-cell adhesion (Simoni et al. 1997).  There are three and seven potential 
glycosylation sites on the extracellular domain of the FSHR and LHR, respectively, with 
only one being highly conserved.  However, these sites do not appear to be necessary for 
ligand binding (Davis et al. 1995; Simoni et al. 1997).  The transmembrane domain 
consists of seven hydrophobic motifs of 20-25 amino acids which become the α-helices, 
three of the seven (motifs 2-4) being highly conserved between LHR and FSHR (~70%).  
The C-terminal domain is thought to be involved in possible phosphorylation events and 
membrane attachment (Simoni et al. 1997).   
 There is evidence for both FSHR and LHR transcripts that differ in size, 
suggesting splice variations and/or different polyadenylation sites.  Whatever the 
mechanism, these variations can lead to alterations in ligand binding capacity and 
receptor efficiency (Hillier et al. 1994; Simoni et al. 1997). 
Gonadotropin receptor expression is cell-specific    
 The FSHR is limited in expression to Sertoli cells in the testes and granulosa cells 
in the ovary.  In the granulosa cells, there is an expression dichotomy depending upon the 
level of expressed FSH; a low dose of FSH up-regulates FSHR gene expression whereas 
a high dose of FSH down-regulates FSHR gene expression up to the time of luteinization 
when FSHR protein becomes undetectable (Hillier et al. 1994; Simoni et al. 1997).  The 
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LHR is expressed in theca and granulosa cells of antral follicles in the ovary, as well as 
Leydig cells of the testes (Hillier et al. 1994).   
Receptor-protein interaction 
 Through mutagenesis studies, specific β-subunit regions of FSH and LH have 
been identified as important for receptor binding.  These include F33, R35, R42, S43, and 
K44 for LH, and amino acids 93-99 of both LH and FSH (Rose et al. 2000).  The amino 
acids present in positions 93-99 are thought to wrap around the α-subunit like a “seat-
belt” and allow for stabilization of receptor-protein binding (Simoni et al. 1997; Rose et 
al. 2000).  Some researchers also suggest an important role of the common α-subunit in 
both receptor binding and in hormone action, as a result of glycosylation (Bishop et al. 
1994; Valove et al. 1994; Zeng et al. 1995). 
The current accepted model of receptor activation suggests hormone binding and 
receptor activation are separate events involving separate receptor protein domains 
(Simoni et al. 1997).  Using chimeric receptors, the extracellular domain was determined 
to be the sole contributor to ligand binding.  Braun et al. (1991) suggested LRR 10 of the 
extracellular domain was the region that conferred binding specificity.  Receptor 
activation and signal transduction have both been designated to the transmembrane 
domain, but the importance of specific motiffs for each action has been disputed (Ji and Ji 
1995; Rozzell et al. 1995).  There are multiple theories proposed to the exact binding 
mechanism, including a conformational change of the bound ligand eliciting signal 
transduction (Braun et al. 1991; Cosowsky et al. 1995), and the LRR form into a shape 
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complementary to the ligand allowing attachment based on complimentary charges (Jiang 
et al. 1995).      
There has been limited evidence of any cross reactivity between FSH and the 
LHR and vice versa, suggesting tight regulatory control.  Activating the LHR with FSH 
or FSHR with LH has been limited to an excess of gonadotropin, specifically seen in 
diseased states.  Conversely, fish gonadotropin receptors exhibit adaptive mechanisms 
where a gonadotropin can activate the opposite receptor (Bogerd et al. 2005). 
 Signal transduction includes production of cyclic adenosine monophosphate 
(cAMP) as a secondary messenger, made evident by in vitro treatment of Sertoli and 
granulosa cells with FSH (Means et al. 1980).  The cAMP signal transduction pathway 
(Figure 1.3, adapted from Simoni et al. 1997) results when cAMP is produced by 
adenylyl cyclase that has been stimulated by the stimulatory subunit of the G-protein.  
cAMP activates protein kinase A (PKA) in the female gonad and PKC in Sertoli cells, 
which begins phosphorylation events leading to alteration in transcription patterns within 
the genome.  Some transcription factors that are activated from FSH and LH include 
cAMP responsive elements binding proteins and modulators which assist in regulation of 
hormone receptor expression, as well as aromatase synthesis (Simoni et al. 1997).  Other 
genes that may be induced as a result of FSH or LH stimulation are estrogen receptor 2, 
inhibin α, PTGS2 (COX-2 associated), CYP19A1 (estrogen biosynthesis), HSD3B1 
(progesterone synthesis), FSHR, and LHR (Mihm et al. 2006; Nimz et al. 2010). 
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Figure 1.3 Cellular responses to FSH engaging G-protein coupled FSHR.  Intracellular 
response is mediated through AC which converts ATP to cAMP with the help of Gs.  cAMP then 
activates PK, which enters the nucleus to phosphorylate transcription factors.  In the case of FSH, 
the transcription factors trigger transcription of aromatase, which mediates the conversion of 
androgen into estrogen, which affects the production of FSH in a negative feedback manner.  
Abbreviations: FSHR: FSH receptor; AC: adenylyl cyclase; cAMP: cyclic AMP; Gs: stimulatory 
subunit of G protein. 
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CHAPTER TWO 
PRODUCTION AND ANALYSIS OF RECOMBINANT BOVINE FOLLICLE 
STIMULATING HORMONE FROM TWO HETEROLOGOUS HOSTS  
 
Abstract 
 Follicle stimulating hormone (FSH) is a heterodimeric pituitary-derived 
glycoprotein hormone that is responsible for growth and maturation of follicles in 
females and steroidogenesis in males.  FSH is harvested from pituitary glands of 
slaughtered animals and used in superovulatory protocols.  This method of collection has 
many drawbacks, including contamination with other pituitary proteins, inconsistencies 
between batches, and the possibility for disease transmission.  Recombinant bovine FSH 
(bFSHβα) was produced from bacteria and yeast heterologous expression systems, and 
the ovarian weight gain biological activity assay was performed.  Bacterial-derived 
rbFSHβα was found to increase rat ovarian weight when compared to vehicle-only 
control rats, as well as pituitary-derived FSH treated rats, suggesting the recombinant 
protein retains biological activity.  Yeast-derived rbFSHβα did not increase rat ovarian 
weights when compared to vehicle-only control rats, however, lack of biological activity 
cannot be concluded because the pituitary-derived FSH treated rats (positive control) did 
not demonstrate an increase in ovarian weight either.   
Introduction 
 FSH is a heterodimeric pituitary-derived glycoprotein hormone that is responsible 
for growth and maturation of follicles in females and steroidogenesis in males.  FSH is 
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the product of two genes which encode distinct subunits (α and β) that are non-covalently 
associated post-protein synthesis.  The α-subunit is conserved within this family of 
glycoprotein hormones [luteinizing hormone, human chorionic gonadotropin (hCG), and 
thyroid stimulating hormone] whereas the β-subunit is different and confers receptor 
specificity (Pierce and Parsons 1981; Rose et al. 2000).   
FSH is used in the cattle industry as an integral part of the superovulation 
protocol.  At the beginning of a follicular wave, pituitary-derived porcine FSH (adequate 
species cross-reactivity has been demonstrated) is administered to trigger the 
development of more than one dominant follicle (typical estrous cycle results in a single 
dominant follicle and ovulation).  FSH has conventionally been derived from pituitary 
tissue, despite concerns that include contamination with other pituitary hormones such as 
LH (Kafi and McGowan 1997; Galli et al. 2003; Adams and Boime 2008), batch-to-batch 
variation (Murphy et al. 1984; Kanitz et al. 2002; Galli et al. 2003), and potential for 
prion transmission (the causative agent of bovine spongiform encephalopathy; Galli et al. 
2003; Adams and Boime 2008).  Here, we provide evidence that a recombinant FSH 
could provide a safe alternative that is devoid of contaminating pituitary hormones for 
superovulation protocols. 
Materials and Methods 
Bacterial 6-his tagged protein production 
A fusion construct of bovine FSH with the β subunit directly upstream of the α- 
subunit (to yield bFSHβα) was generated by PCR using cDNA from bovine anterior 
pituitary tissue (see Table D.2 for primer sequences).  This gene product was ligated into 
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pQE30 for expression of an N-terminal six-histidine (6his) tagged fusion protein.  
Following transformation of the construct into M15 bacterial cells, cultures were grown 
to OD600 of 0.6 in ECPM1 media (Barnard and Payton 1995) at 37oC, induced with 
isopropylthio-β-D-galactoside (IPTG; 250 µM), and protein expressed overnight at room 
temperature.  After expression, cells were collected by centrifugation (2000 x g; 30 min; 
4oC), lysed by cell disruption in a French press (28,000 psi), and insoluble material was 
separated by centrifugation (10,000 x g, 30 min, 4oC).  bFSHβα in the soluble fraction 
was purified by nickel affinity chromatography (Ni-NTA Agarose, Qiagen, Valencia, 
CA) yielding a partially pure protein.  Purification fractions and induced cell pellets were 
analyzed using 12% SDS-PAGE stained with Coomassie Brilliant Blue.  Protein was 
transferred from acrylamide gels to nitrocellulose at 16 V for 40 min (TransBlot SD Semi 
Dry Transfer Cell, BioRad, Hercules, CA).  Western blotting was performed with 
blocking (1% non-fat milk) for 1 hr, and the following antibodies: 1o mouse α-6his 
(1:2000) or 1o α-ovine FSH (1:250) incubation for 1 hr, and 2o goat-α-mouse (GαM) 
horseradish peroxidase (HRP; 1:5000) incubation for 1 hr.  HRP was visualized using 
SuperSignal® West Pico Chemiluminescent Substrate Kit (Pierce®, Rockford, IL).  
Protein concentration was determined using BCA Assay kit (Pierce®, Rockford, IL) with 
bovine serum albumin as a standard, and lyophilized in 50 µg aliquots for storage.   
Bacterial GST-tagged protein production 
 A fusion construct of bovine FSH with the β subunit directly upstream of the α-
subunit (to yield bFSHβα) was generated by PCR using cDNA from bovine anterior 
pituitary tissue (see Table D.2 for primer sequences).  This gene product was ligated into 
61 
pGEX4T-1 for expression of a glutathione-S-transferase (GST) tagged fusion protein 
(GST is a 27 kDa protein).  Supercoiled plasmid was transformed into BL21(DE3) 
competent cells via electroporation and positive transformants containing bFSHβα were 
confirmed initially by PCR on whole cells and then by DNA sequencing (Clemson 
University Genomics Institute-CUGI).  Following transformation of the construct, 
cultures were grown to OD600 of 0.6 in terrific broth media (1% tryptone, 2.5% yeast 
extract, 0.4% glycerol, 17 µM KH2PO4, 72 µM K2HPO4) at 37oC, induced with IPTG 
(250 µM), and protein expressed overnight at room temperature.  After expression, cells 
were collected by centrifugation (2000 x g; 30 min; 4oC), lysed by sonication, and 
insoluble material was separated by centrifugation (10,000 x g, 30 min, 4oC).  bFSHβα in 
the soluble fraction was purified by affinity chromatography utilizing the GST tag 
incorporated by the expression vector.  Purification fractions and induced cell pellets 
were analyzed using 12% SDS-PAGE stained with Coomassie Brilliant Blue.  Protein 
was transferred from acrylamide gels to nitrocellulose at 16 V for 40 min (TransBlot SD 
Semi Dry Transfer Cell, BioRad, Hercules, CA).  Western blotting was performed with 
blocking (1% non-fat milk) for 1 hr, and the following antibodies: 1o α-GST-biotin 
(1:2000) or 1o α-ovine FSH (1:250) incubation for 1 hr, and 2o α-biotin HRP (1:5000) 
incubation for 1 hr.  HRP was visualized using SuperSignal® West Pico 
Chemiluminescent Substrate Kit (Pierce®, Rockford, IL).  Protein concentration was 
determined using BCA Assay kit (Pierce®, Rockford, IL).  Protein was quantified using 
BCA assay (Pierce®, Rockford, IL). 
Yeast protein production 
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A fusion construct of bovine FSH with the β subunit directly upstream of the α-
subunit (to yield bFSHβα) was generated by PCR using cDNA from bovine anterior 
pituitary tissue (see Table D.5 for primer sequences).  This gene product was ligated into 
pPICZαA for expression of a C-terminal 6his tagged fusion protein.  Plasmid (5 µg) was 
linearized using BstX1 to prepare for transformation and subsequent integration into the 
Pichia pastoris genome.  GS115 P. pastoris competent cells were transformed by 
electroporation (1500 V; ECM830, BTX, Holliston, MA).  Transformants were then 
plated on yeast extract peptone dextrose media containing 100 µg/ml Zeocin and 
incubated at 30oC for 3-10 days.  Positive transformants containing bFSHβα were 
determined using PCR on whole cells and confirmed by DNA sequencing (CUGI).  The 
methanol utilization phenotype was determined by growth on media containing histidine 
and either dextrose or methanol; bFSHβα was found to exhibit the MutS phenotype, 
meaning it utilizes methanol for protein expression at a relatively slow rate when 
compared to wild-type.  A culture of buffered minimal glycerol was seeded with a single 
positive colony and grown to OD600 of 2-6 (30oC, 20 h).  The cells were harvested by 
centrifugation (1500 x g, 10 min, 27oC) and resuspended to an OD600 of 1 in buffered 
minimal methanol media.  Cells were induced with 0.5% methanol and incubated at 30oC 
(1-4 days).  Cultures were then harvested by centrifugation (1500 x g, 10 min), 
resuspended in 20 mM Tris (pH 7.4), and cells loaded into a bead beating chamber and 
lysed with 0.5 mm glass beads for 3 min (Model 1107900, BioSpec Products Inc, 
Bartlesville, OK).  The resulting slurry was centrifuged (200 x g, 10 min), and soluble 
material was separated from the glass beads and insoluble material by centrifugation 
63 
(10,000 x g, 30 min, 4oC).  Protein was purified beginning with ion exchange HPLC 
(QHP 5 ml column; GE Healthcare, Piscataway, NJ) using a 10-40% gradient of 1 M 
NaCl with protein eluted in 20 mM Tris, pH 7.4.  Size exclusion HPLC followed using 
G50 resin (GE Healthcare, Piscataway, NJ) with protein eluted in PBS (pH 7.4).  Protein 
was analyzed from spent culture media, induced cell pellet, and all purification fractions 
using 12% SDS-PAGE stained with Coomassie Brilliant Blue.  Protein was transferred 
from acrylamide gels to nitrocellulose at 16 V for 40 min (TransBlot SD Semi Dry 
Transfer Cell, BioRad, Hercules, CA).  Western blotting was performed as follows: 1% 
non-fat milk block for 1 hr, 1o mouse α-6his antibody (1:2000) or 1o α-ovine FSH (1:250) 
incubation for 1 hr, and 2o GαM HRP incubation for 1 hr.  HRP was visualized using 
SuperSignal® West Pico Chemiluminescent Substrate Kit (Pierce®, Rockford, IL).  
Protein was quantified using BCA assay (Pierce®, Rockford, IL) and stored in PBS at -
20oC until further use.  
In vivo biological assay 
To assess biological activity, the rat ovarian weight gain assay was utilized 
(Steelman and Pohley 1953).  Briefly, 3 µg recombinant bFSHβα or commercially-
available native  pituitary-derived porcine FSH (Bioniche Animal Health, Belleville, 
Ontario, Canada) was administered to peri-mature (Day 20-22) Sprague-Dawley female 
rats in three 0.5 ml IP injections in saline plus hCG (100 IU/ml) 24 hours apart.  Inclusion 
of hCG serves to increase sensitivity of the rat to the exogenous FSH and was provided to 
all subjects prior to FSH treatment.  All animals were kept 5 to a cage with ad libitum 
food and water, at a constant temperature (22oC) and light cycle (12 h light).  All animal 
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protocols were conducted in accordance to IACUC regulations.  Rats were euthanized 24 
hours after the third injection (72 hours from initiation of treatment) and ovaries excised 
and weighed.  Ovarian weights were analyzed using Student’s t-test to identify 
differences among groups (α = 0.05).   
Results 
Protein production  
Recombinant bacterial bFSHβα (rbbFSHβα)-6his protein was estimated to be 
~10% pure, as judged by Coomassie staining (Figure 2.1) though this estimation is likely 
inaccurate due to poor stain binding by bFSHβα.  Purification of rbbFSHβα-GST protein 
was complicated by two issues.  First, protein did not bind efficiently to the GST-affinity 
column during protein purification.  Second, an excess of free GST was produced from 
the bacteria during induction (Figure 2.2).  Re-sequencing revealed a frame-shift in the 
GST gene, resulting in the loss of a functional protein, explaining loss of binding.  Re-
cloning attempts of the expression cassette were unsuccessful.  
Small-scale expression cultures revealed that adequate amounts of recombinant 
yeast bFSHβα (rybFSHβα) protein were produced after 1 day of induction (Figure 2.3).  
Purified protein from a large-scale expression was concentrated at ~73 µg/ml and purity 
was ~ 90% (Figure 2.4).   
In vivo biological assay-Trial 1 
Bacterial-derived bFSHβα-6his protein (3 µg) was delivered over three doses 
(each 24 h apart) to Sprague-Dawley female rats (n = 10).  rbbFSHβα-6his treatment 
triggered an increase in rat ovarian weights when compared to control rats (22.0 ± 1.2 mg  
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Figure 2.1 Purification fraction of rbbFSHβα-6his from M15 bacterial cells.  
A: 15% SDS-PAGE stained with CBB, B: Pituitary porcine FSH (pFSH) preparation western blot 
probed with α-ovine-FSH 1o (1:250), rbbFSHβα-6his preparation western blot probed with α-
ovine FSH 1o (1:250), rbbFSHβα-6his preparation western blot probed with α-6his tag 1o 
(1:2000). 
 
 
Figure 2.2 rbbFSHβα-GST protein produced from BL21(DE3) bacterial cells.  A: Western 
blot of GST purification fractions probed with 1o α-GST Biotin antibody (1:2000) and 2o HRP-
Biotin (1:5000). B: Coomassie stain of 12% SDS-PAGE.  
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Figure 2.3 Small-scale expression study of rybFSHβα-6his. 
Protein was induced at 30oC from P. pastoris yeast cells for 1-6 
days. Analysis was performed on samples of pelleted cells (CP) 
or spent culture supernatant (CS) by western blot using 1o mouse 
α-6his (1:2000), 2o GαM HRP (1:5000).  
 
 
Figure 2.4 rybFSHβα-6his protein induced from P. 
pastoris. Yeast cells were induced for 1 day at 28oC.  Cell pellet 
was lysed using bead beater and protein was purified from 
soluble fraction using ion exchange and size exclusion HPLC. A: 
CBB stain of purification fractions, B: Western blot of 
purification fractions using 1o mouse α-6his (1:2000), 2o GαM 
HRP (1:5000). 
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vs. 15.5 ± 0.8 mg, respectively; p < 0.05), and a ~15% increase over native pituitary-
derived FSH (18.7 ± 1.3 mg; p < 0.05; Figure 2.5).  There were no overall differences in 
whole rat weights for recombinant protein treatment (48.1 ± 1.0 g) or native protein 
treatment (46.2 ± 1.1 g) when compared to control rats (47.8 ± 0.6 g; p > 0.05). 
In vivo biological assay-Trial 2 
 Yeast-derived bFSHβα-6his protein (10 µg) was delivered over three doses (each 
24 h apart) to Sprague-Dawley female rats (n = 10).  Analysis suggested whole rat 
weights decreased with both pituitary-derived and recombinant FSH treatments (44.8 ± 
2.4 g and 47.2 ± 3.6 g, respectively) when compared to the vehicle-only rats (53.0 ± 3.6 
g; p < 0.1; Figure 2.6).  Pituitary-derived FSH (0.76 ± 0.09 mg/g) and rybFSHβα-6his 
(0.79 ± 0.16 mg/g) treatments triggered an overall decrease in rat ovarian weights (mg) as 
a portion of the rat’s body weight (g) when compared to control rats (0.84 ± 0.13 mg/g; p 
> 0.05; Figure 2.7).   
Discussion 
The data from Trial 1 suggest that in the rodent model, the lack of glycosylation 
of the recombinant protein did not eliminate biological activity, as the ovarian weights in 
treated rats increased after delivery of bacterial-derived recombinant bFSHβα (Figure 
2.5).  It is possible that the contaminating proteins in the sample had some consequences 
on ovarian weight.  The yeast-derived protein used in Trial 2 cannot be assumed to be 
inactive based on the data because the native, pituitary FSH (positive control) group did 
not trigger an increase in ovarian weight, as expected (Figure 2.7).  In addition, rat body 
weights were increased in the vehicle-only controls when compared to both treatments, 
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Figure 2.5 Ovarian weights from rats injected with rbbFSHβα-6his in Trial 1. Ovarian weights of peri-mature female rats injected 
with bacterial-derived recombinant bFSHβα-6his, native pituitary-derived commercially-available pFSH, or hCG (100 IU/ml).  Dosage of 
FSH (3 µg/animal for both recombinant and native) was based on adjustment of dose commonly given to dairy cattle. **Significant 
difference for treatment vs. control (p < 0.05); n = 20 for each group. 
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Figure 2.6 Rat body weights after injection with rybFSHβα-
6his in Trial 2. Whole rat body weights post-mortem after 
treatment with either vehicle only (hCG), 10 µg pituitary-derived 
pFSH, or 10 µg rybFSHβα-6his. **Significant difference for 
treatment vs. control (p < 0.05); n = 10 for each group. 
 
Figure 2.7 Ovarian weights of rats injected with 
rybFSHβα-6his in Trial 2. Rat ovarian weights (mg)/body 
weight (g) post-mortem after treatment with either vehicle only 
(hCG), 10 µg pituitary-derived pFSH, or 10 µg rybFSHβα-6his. 
*Significant difference for treatment vs. controls (p < 0.1); n = 
10 for each group. 
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which may explain the increase in ovarian weights (Figure 2.6).  Conversely, the yeast 
cells did not secrete this protein as expected, suggesting the rybFSHβα may have been 
improperly glycosylated (hyper- or hypo-).  The improper glycosylations could account 
for the lack of bioactivity of the recombinant protein. 
The biological half-life of FSH has conventionally been attributed to the 
incorporation of sialic acid into the N-linked post-translational glycosylations of the 
mammalian protein (Green and Baenziger 1988; Morell et al. 1971; Sinclair and Elliot 
2005).  Bacteria do not glycosylate their proteins and yeast tend to hyperglycosylate their 
proteins, with neither variety exactly mimicking a mammalian protein (Porro 2005).  The 
lack of proper glycosylations is what has limited use of non-eukaryotic heterologous 
protein expression systems, as there are concerns that the protein will not be active long 
enough in vivo to cause desired effects.   
In vivo activity of recombinant bFSH has been reported, and a few production 
systems have been utilized to produce a biologically active protein, including Chinese 
Hamster Ovary (CHO) cells and plant systems.  Both Looney et al. (1988) and Wilson et 
al. (1993) superovulated cattle with a recombinant bFSH prepared from CHO cells, and 
found it to increase the number of recovered embryos.  Even though CHO cells are a 
mammalian system, they are not the ideal protein production system for use in 
mammalian industries because of their need for fetal bovine serum (FBS) in culture 
media and the potential of that to transmit disease-causing organisms (Balen 2002).  
Recently, active human FSH (hFSH) was produced from modified CHO cells that can 
grow in the absence of FBS (Kim et al. 2010).  Dirnberger et al. (2001) produced 
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recombinant bFSH from transgenic tobacco plants and found the recombinant protein 
increased the number of recovered oocytes, but not as efficiently as a traditional hyper-
stimulatory drug, pregnant mare serum gonadotropin.    
Production of hFSH typically involves CHO heterologous system, and has 
recently focused on the addition of extra glycosylations to enhance the protein’s 
biological activity, thereby reducing the amount or frequency of FSH injections for 
superovulation (Fares et al. 1992; Devroey et al. 2004; Lemke et al. 2008).  Other reports 
have produced recombinant ovine and porcine FSH, but only in vitro data was reported, 
lending limited insight to glycosylations and their link to biological half life (Fidler et al. 
1998; Richard et al. 1998; Fidler et al. 2003).      
Conclusions 
Having shown targeted effects in a rodent model, further research with bacterial-
derived recombinant bFSHβα would be warranted using a bovine model, the final 
destination for the exogenous FSH produced here.  This bioactive heterologous protein 
may, in the future, serve as a safer, more pure alternative to pituitary-derived FSH.  
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CHAPTER THREE 
PRODUCTION AND ANALYSIS OF RECOMBINANT BOVINE LUTEINIZING 
HORMONE FROM TWO HETEROLOGOUS HOSTS 
 
Abstract 
 Luteinizing hormone (LH) is a glycoprotein produced in the anterior pituitary that 
is responsible for ovulation of the dominant follicle in the ovary, and the release of 
testosterone from Leydig cells within the testes.  LH is composed of 2 subunits (α and β) 
that are noncovalently associated post-translation.  The stimulatory agent of LH, 
gonadotropin releasing hormone (GnRH), is used in the cattle industry to synchronize 
ovulation within cattle populations, however, studies have shown that GnRH is not as 
consistent as LH in this task.  Here, we describe successful efforts to produce highly pure 
recombinant bovine LH (bLH) from two heterologous hosts, bacteria and yeast.  Each of 
these bLH preparations was used to determine in vitro (receptor binding and activation 
capacity) and in vivo (biological) activity when compared to a commercially available LH 
pituitary preparation.   
Introduction 
LH is a heterodimeric glycoprotein hormone produced within the anterior 
pituitary.  LH, along with follicle stimulating hormone (FSH), thyroid stimulating 
hormone, and chorionic gonadotropin, is composed of two subunits produced from 
different genes that are non-covalently associated post-translation.  The α-subunit within 
this family of hormones is conserved, whereas the β-subunit is specific for each protein, 
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conferring receptor specificity (Pierce and Parsons 1981).  LH is responsible for 
ovulation of the dominant follicle within the ovary, and the release of testosterone from 
Leydig cells within the testes.  LH is strictly regulated by GnRH which is released from 
the hypothalamus and travels the hypothalamic-hypophyseal axis (Pierce and Parsons 
1981; Simoni et al. 1999).  
GnRH, rather than LH, is used in bovine superovulatory protocols to trigger 
ovulation because of the tight consequential regulation between the two hormones; 
however, it also has been linked to the regulation of FSH, albeit a looser correlation 
(Clarke and Pompolo 2005).  Despite being the conventional ovulatory stimulator in 
synchronization protocols (Pursley et al. 1995), GnRH has been shown to be less 
effective than pituitary LH at stimulating ovulation (56% and 78%, respectively) in dairy 
heifers, however both products induced a new follicular wave within 2 days post-
treatment if that treatment resulted in ovulation (Martinez et al. 1999).  GnRH is used in 
bovine superovulation because of problems documented of pituitary-derived hormones, 
including contamination of other pituitary hormones (Kafi and McGowan 1997; Galli et 
al. 2003; Adams and Boime 2008), batch inconsistencies (Murphy et al. 1984; Kanitz et 
al. 2002; Galli et al. 2003), and the potential to spread disease causing agents, such as 
prions (Galli et al. 2003; Adams and Boime 2008).  These issues are of enough concern 
to warrant the ban of such products in some European countries (Galli et al. 2003).  To 
combat these issues, recombinant proteins have been manufactured for superovulatory 
use (main focus to date has been FSH), but have not become widespread yet.  A 
recombinant preparation would need to be produced from a mammalian vector (namely 
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Chinese hamster ovary cells) to look most identical to the native protein, but the potential 
for spreading disease via prions may still be present from the inclusion of fetal bovine 
serum in the culture media (Balen 2002).  Instead, it may be possible to produce a 
recombinant protein from a non-mammalian host (such as bacteria or yeast) that acts 
identical, if not better, than a protein produced from a mammalian vector, eliminating the 
possibilities of disease transmission.  Recombinant proteins also eliminate another 
notable problem of pituitary-derived hormones, that of contamination of other pituitary 
hormones.  The issue of hormone contamination and whether a superovulatory 
preparation needs both FSH and LH to be most effective has been debated (Ward 1986; 
Takagi et al. 2001; Kanitz et al. 2002).  A recombinant preparation of bLH would be 
useful to the bovine superovulation industry. 
In this study, bacterial- (rbbLHβα) and yeast-derived (rybLHβα) recombinant 
versions of LH were produced and their activity compared using an in vitro bovine 
granulosa cell assay to measure gene expression profiles.  The genes considered included 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH, which served as the reference 
gene), CYP19A1, a marker for estrogen biosynthesis, and FSH and LH receptor (FSHR 
and LHR, respectively).  Additionally, an in vivo biological activity assay was performed 
to measure ascorbic acid oxidation in the rodent ovary. 
Materials and Methods 
Vector construction 
 The bLHβ, and the common α subunit were amplified via PCR using bovine 
anterior pituitary cDNA (primer sequences can be found in Table D.2 and D.5).  Using 
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novel restriction enzyme sites, bLHβ was cloned directly upstream of α in a bacterial 
expression vector (pGEX4T-1) and a yeast expression vector (pPICZαA).       
E. coli expression 
Supercoiled plasmid was transformed into BL21(DE3) competent cells via 
electroporation and positive transformants containing bLHβα were confirmed initially by 
PCR on whole cells and then by DNA sequencing (Clemson University Genomics 
Institute—CUGI).  Following transformation of the construct, cultures were grown to 
OD600 of 0.6 in ECPM1 media (Barnard and Payton 1995) at 37oC, induced with IPTG 
(250 µM), and protein expressed overnight at room temperature.  After expression, cells 
were collected by centrifugation and lysed by cell disruption and insoluble material was 
separated by centrifugation (10,000 x g, 30 min, 4oC).  bLHβα in the soluble fraction was 
purified by affinity chromatography utilizing the N-terminal glutathione s-transferase 
(GST) tag incorporated by the expression vector.  Protein was then purified using ion 
exchange HPLC (QHP 5 ml column; GE Healthcare, Piscataway, NJ) using a 10-40% 
gradient of 1 M NaCl with protein eluted in 20 mM Tris, pH 7.4.  Size exclusion HPLC 
followed using G50 resin (GE Healthcare, Piscataway, NJ) with protein eluted in PBS 
(pH 7.4).  Purification fractions and induced cell pellets were analyzed using 12% SDS-
PAGE stained with Coomassie Brilliant Blue.  Protein was transferred from acrylamide 
gels to nitrocellulose at 16 V for 40 min (TransBlot SD Semi Dry Transfer Cell, BioRad, 
Hercules, CA).  Western blotting was performed with blocking (1% non-fat milk) for 1 
hr, and the following antibodies: 1o α-GST-biotin (1:2000) or 1o α-ovine FSH (1:250) 
incubation for 1 hr, and 2o α-biotin horseradish peroxidase (HRP; 1:5000) incubation for 
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1 hr.  HRP was visualized using SuperSignal® West Pico Chemiluminescent Substrate 
Kit (Pierce®, Rockford, IL).  Protein was quantified using BCA assay (Pierce®, 
Rockford, IL). 
P. pastoris expression 
 pPICZαAbLHβα plasmid (5 µg) was linearized using BstX1 to prepare for 
transformation and subsequent integration into the Pichia  pastoris genome.  GS115 P. 
pastoris competent cells were prepared and transformed by electroporation (ECM830, 
BTX, Holliston, MA, 1500 V).  Transformants were then plated on yeast extract peptone 
dextrose media containing 100 µg/ml Zeocin and incubated at 30oC for 3-10 days.  
Positive transformants containing bLHβα were determined using PCR on whole cells and 
confirmed by DNA sequencing (CUGI).  The methanol utilization phenotype was 
determined by growth on media containing histidine and either dextrose or methanol; 
bLHβα was found to exhibit the Mut+ phenotype, meaning it utilizes methanol to express 
heterologous proteins at a normal rate when compared to wild-type.  A culture of 
buffered minimal glycerol was seeded with a single positive colony and grown until 
OD600 of 2-6 (30oC, 20 h).  The cells were harvested by centrifugation (1500 x g, 10 min, 
27oC) and resuspended to an OD600 of 1 in buffered minimal methanol media.  Cells were 
induced with 0.5% methanol and incubated at 30oC (1-6 days).  Cultures were then 
harvested by centrifugation (1500 x g, 10 min), resuspended in 20 mM Tris (pH 7.4), and 
cells loaded into a bead beating chamber and lysed with 0.5 mm glass beads for 3 min 
(Model 1107900, BioSpec Products Inc, Bartlesville, OK).  The resulting slurry was 
centrifuged (200 x g, 10 min), and soluble material was separated from the glass beads 
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and insoluble material (10,000 x g, 30 min, 4oC).  Protein was purified beginning with 
ion exchange HPLC (QHP 5 ml column; GE Healthcare, Piscataway, NJ) using a 10-40% 
gradient of 1 M NaCl with protein eluted in 20 mM Tris, pH 7.4.  Size exclusion HPLC 
followed using G50 resin (GE Healthcare, Piscataway, NJ) with protein eluted in PBS 
(pH 7.4).  Purification fractions and induced cell pellets were analyzed using 12% SDS-
PAGE stained with Coomassie Brilliant Blue.  Protein was transferred from acrylamide 
gels to nitrocellulose at 16 V for 40 min (TransBlot SD Semi Dry Transfer Cell, BioRad, 
Hercules, CA).  Western blotting was performed with blocking (1% non-fat milk) for 1 
hr, and the following antibodies: 1o mouse α-6his (1:2000) or 1o α-ovine FSH (1:250) 
incubation for 1 hr, and 2o goat-α-mouse (GαM) HRP (1:5000) incubation for 1 hr.  HRP 
was visualized using SuperSignal® West Pico Chemiluminescent Substrate Kit (Pierce®, 
Rockford, IL).   Protein was quantified using BCA assay (Pierce®, Rockford, IL). 
In vitro assay     
Bovine ovaries (~1 kg) were obtained from a local abattoir (Brown Packing Co., 
Gaffney, SC) and rinsed in PBS, 70% ethanol, and M199 with 0.1% BSA.  Follicles >10 
mm were removed and granulosa cells isolated and collected in M199 (0.1% BSA, 10 
µg/ml DNase, 50 U/ml Heparin), followed by filtration (100 µm cell strainer, BD 
Biosciences, Billerica, MA).  Granulosa cells were then washed four times in M199 
(0.1% BSA) and resuspended in M199 (0.1% BSA, 1 µg/ml insulin, 10% FBS).  Cells 
were counted using a hemocytometer and 3 x 105 cells were plated in 24 well culture 
plates (amine coating; BD Biosciences, Billerica, MA).  Treatments (in 100 µl vehicle) 
were as follows: PBS (vehicle), 50 µunits pituitary ovine LH (Sigma, St. Louis, MO), 
82 
rbbLHβα (20 µg), and rybLHβα (20 µg).  Treatments were added and cells were plated 
overnight at 37oC.  After four days, cells were trypsinized, counted, and stored at -20oC 
until analysis.  All reagents were purchased from Sigma (St. Louis, MO) unless otherwise 
noted.  Culture supernatant was assayed for progesterone content using a Coat-A-Count® 
progesterone RIA (Siemens Healthcare Diagnostics, Deerfield, IL) that measures binding 
competition of radiolabeled progesterone to antibody. 
qReal Time PCR   
 Total RNA was isolated from granulosa cell pellets using AurumTM Total MRNA 
Mini Kit (BioRad, Hercules, CA), followed by RQ1 RNase-free DNase treatment for 30 
min at 37oC (10 units; Promega, Madison, WI).  DNA degradation was confirmed using 
conventional PCR and primers specific to the reference gene.  RNA was quantified using 
a NanoDrop 8000 Spectrophotometer (ThermoScientific, Wilmington, DE).  First strand 
cDNA was synthesized from 30 ng total RNA in 20 µl reaction using ProtoScript® MuLV 
First Strand cDNA Synthesis kit (New England Biolabs, Ipswich, MA) using a random 
hexamer primer (50 µM), 1 unit reverse transcriptase, and the following conditions: 
denaturation at 70oC for 5 min, annealing at 25oC for 5 min, extension at 42oC for 1 hr, 
inactivation of reverse transcriptase at 80oC for 10 min.  cDNA was then treated with 
RNaseH for 20 min at 37oC (New England Biolabs, Ipswich, MA). 
 Gene specific primers were used for the following genes: GAPDH, CYP19A1, 
FSHR, and LHR (Nimz et al. 2010; Table D.6).  Quantitative real time PCR (qPCR) was 
conducted using iScriptTM RT-PCR Kit with SYBR® Green (BioRad, Hercules, CA) in an 
iQ5 iCycler Multicolor Real-Time PCR Detection System (BioRad, Hercules, CA) under 
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the following cycling conditions: pre-incubation at 95oC for 5 min, 40 cycles of 
denaturation at 95oC for 10 s, fluorescence collection at 60oC for 30 s.  The reaction used 
6 µl cDNA and 5 µM each forward and reverse primers in a 26 µl reaction.  The melt 
curve analysis was obtained to ensure appropriate products were made with no primer 
dimerization.  Primer efficiencies were determined to be >95% for each primer set.  
qPCR products were visualized by agarose gel electrophoresis (1%) and stained with 1 µg 
ethidium bromide.     
In vivo assay 
To assess biological activity, the LH ovarian ascorbic acid depletion assay was 
utilized (Goldstein and Sturgis 1961).  All animals were kept three to a cage with ad 
libitum food and water, at a constant temperature (22oC) and light cycle (12 h light).  All 
animal protocols were conducted in accordance to IACUC regulations.  Briefly, 26 day-
old Holtzman rats were made to be pseudopregnant by administration of PMSG (50 IU) 
followed by hCG (25 IU) 48 h later (either 0.5 cc or 0.25 cc IP injections in 0.9% saline, 
respectively).  Four days after the last injection, each rat’s right ovary was surgically 
removed, immediately placed on ice, and stored at -20oC until further analysis.  Directly 
following unilateral ovariectomy, each rat randomly received an LH treatment (0.25 cc 
IV injection in 0.9% saline).  The treatments were as follows: PBS (vehicle), pituitary 
ovine LH (50 µunits), rbbLHβα (20 µg), or rybLHβα (20 µg).  Three hours later, each 
rat’s left ovary was surgically removed and prepared as previously described for storage.  
Following the second ovariectomy, rats were euthanized following appropriate animal 
guidelines.  Each ovary was homogenized using a Dounce homogenizer (50 passes) and 
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cell lysis was confirmed by visualization by microscopy (10X).  Cellular debris was 
removed by centrifugation (10,000 x g, 10 min, 4oC) and soluble contents were 
deproteinated using 10 kDa NMWL centrifugal unit (Millipore, Jaffrey, NH).  Ascorbic 
acid was measured spectrophotometrically (560nm) from the eluate using an ascorbic 
acid assay kit (MBLI, Woburn, MA).  Briefly, a catalyst oxidizes ascorbic acid in the 
sample into a product that interacts with a probe, causing a colorimetric change.   
Results 
Protein production 
 After optimal expression and purification conditions were determined, highly pure 
bacterial- and yeast-derived LH preparations were obtained.  rbbLHβα was estimated to 
be >90% pure and quantified at 205 µg/ml (Figure 3.1).  An expression time course 
suggested the optimal induction time for rybLHβα was 5-6 days at 28oC (Figure 3.2), and 
purified protein was estimated to be >95% pure and quantified at 207 µg/ml (Figure 3.3).   
In vitro assay 
 After one day of LH treatment, there was a slight increase in transcript level of 
CYP19A1 estrogen biosynthesis gene for all LH treatments (pituitary LH: 0.44-fold 
increase, rbbLHβα: 0.12-fold increase, rybLHβα: 0.40-fold increase).  Transcript level of 
FSHR gene decreased similarly throughout each LH treatment (pituitary LH: 2.5-fold 
decrease, rbbLHβα: 1.2-fold decrease, rybLHβα: 1.3-fold decrease).  Transcript level of 
LHR gene also decreased, but a larger decrease was seen in the pituitary LH and the 
rybLHβα treatments (7.4-fold decrease and 2.9-fold decrease, respectively), as compared 
to the rbbLHβα treatment (1.2-fold decrease; Figure 3.4A).   
85 
 
Figure 3.1 rbbLHβα protein induced from E. coli bacterial 
cells overnight at RT.  Cell pellet was lysed using cell 
disruption and protein was purified from soluble fraction using 
ion exchange and size exclusion chromatography. A: CBB stain 
of final purified fraction. B: Western blot of final purified 
purification fraction using 1o α-GST-Biotin (1:2000), 2o GαM 
HRP (1:5000). 
 
Figure 3.2 Small-scale expression study of rybLHβα in P. 
pastoris yeast.  Protein was induced with the addition of 2% 
galactose at 28oC for 1-6 days.  Analysis was performed on small 
samples of pelleted cells (CP) or spent culture supernatant (CS) 
using 1o mouse α-6his (1:2000), 2o GαM HRP (1:5000).    
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Figure 3.3 rybLHβα protein induced from P. pastoris yeast cells. Protein expression was induced for 5 days at 28oC.  Cell pellet was 
lysed using bead beater and protein was purified from soluble fraction using ion exchange and size exclusion chromatography. A: Silver 
stain of purification fractions. B: Western blot of purification fractions using 1o mouse α-6his (1:2000), 2o GαM HRP (1:5000). 
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Progesterone concentrations were determined by a progesterone RIA of the 
culture supernatant after one day of incubation with the LH treatments.  Cells treated with 
vehicle expressed 21.7 ± 6.4 ng/ml progesterone, compared to 27.1 ± 1.9 ng/ml seen in 
the cells treated with pituitary LH.  Both rbbLHβα and rybLHβα preparations contained 
less progesterone in the culture supernatant (15.9 ± 13.1 ng/ml and 7.7 ± 7.1 ng/ml, 
respectively), with only the rybLHβα protein exhibiting a trend (p < 0.1; Figure 3.4B).   
In vivo assay 
 The relative ovarian ascorbic acid content increased from pre- to post-LH 
treatment for each treatment group, although the increase was modest for this assay.  The 
increase for the vehicle-only treatment (negative control) was 17.6 ± 2.46%.  The highest 
increase was found in the pituitary ovine LH treatment group (23.4 ± 19.5%) with the 
rbbLHβα and the rybLHβα increasing ascorbic acid slightly less (11.3 ± 19.5% and 11.3 
± 7.9%, respectively; Figure 3.5).  
Discussion 
 Granulosa cells of ovarian follicles that are greater than 10 mm are post-deviation, 
suggesting that the follicle will mature to ovulation.  These cells have altered 
predominant surface receptor gene expression from FSHR to LHR and rely on LH to 
reach full maturity (Adams et al. 1992).  Adding a bolus of LH to these cells mimics the 
pre-ovulatory LH surge associated with ovulation, altering the cells from estrogen 
synthesis to progesterone (Nimz et al. 2010).  The CYP19A1 gene, which is associated 
with estrogen biosynthesis, would be expected to decrease after a bolus of LH treatment.  
In our experiment, we see a slight increase in CYP19A1 transcript level.  The decrease in  
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A B  
Figure 3.4 Gene expression profile of bovine granulosa cells isolated from follicles >10 mm and cultured in vitro with LH 
treatment for one day. 
A: Relative fold change of CYP19A1, FSHR, and LHR gene transcripts (GAPDH used as reference gene) after incubation with either 
pituitary ovine LH, rbbLHβα, or rybLHβα treatment. The fold changes are given as the mean of three replicates. B: Progesterone content 
(ng/ml) of culture supernatant.  * Significant difference for treatment vs. control (p < 0.1). 
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Figure 3.5 Biological activity assay for bLH –ovarian ascorbic acid depletion assay. Relative ovarian ascorbic acid post-LH treatment 
when compared to pre-treatment of peri-mature female rats.  Treatments as follows: No LH (vehicle-only control), 50 µunits pituitary 
ovine LH, and 20 µg rbbLHβα and rybLHβα. n = 3 for each group. 
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FSHR transcript levels after treatment with LH was predicted because the granulosa cells 
were obtained from follicles greater than 10 mm which were already predominantly 
expressing LHR.  The nature of these follicles, combined with the LH treatment, suggests 
any residual FSHR expression would be down-regulated.  The full effects of cellular 
luteinization may not have been realized after one day of incubation with LH treatment.  
Complete luteinization of granulosa cells in vitro may take up to 8 days with LH 
(Mamluk et al. 1998), suggesting a longer incubation time in this study may have resulted 
in further differential expression of FSHR and CYP19A1 gene transcripts.   
An increase in LHR transcript level after the addition of LH was a possible 
outcome because LH could trigger up-regulation in an autocrine response.  However, 
after 1 day of LH treatment, LH caused a repression in LHR expression, suggesting an 
autocrine down-regulation.  The potential down-regulation of LHR is also reflected in the 
reduction of progesterone seen in the culture supernatant after 1 day of LH treatment, 
which would support the likelihood of successful LH protein receptor activation.  Others 
have reported a down-regulation of LHR transcript after luteinization of granulosa cells 
in vitro with LH (Mamluk et al. 1998), suggesting luteinized granulosa cells (which 
become the large luteal cells) do not possess as much LHR transcript and may not be 
sensitive to LH.  
The pituitary LH caused the greatest LHR transcript repression, with the rbbLHβα 
exhibiting the smallest LHR transcript decrease.  This difference could be a consequence 
of a higher amount of LH activity in the pituitary LH samples.  The LH activity in the 
crude commercial pituitary LH preparation in units of protein mass is difficult to 
91 
determine given the complexity of the crude material.  Therefore it is difficult to compare 
the product with the recombinant proteins.  A direct comparison of the recombinant 
proteins suggest that rybLHβα caused a greater decrease in LHR receptor than the 
bacterial protein did, suggesting it may be the more active of the two heterologous 
proteins.      
The ovarian ascorbic acid depletion assay is the industry standard for determining 
the activity of LH preparations.  Here, too few animals were used to merit statistical 
significance, so all data obtained should be considered preliminary.  Every treatment 
group resulted in an increase in relative ascorbic acid content from pre- to post-LH 
treatment.  This was unanticipated because LH has been reported to trigger the oxidation 
of ascorbic acid in the rat ovary, resulting in as much as a 46% decrease in ascorbic acid 
content three hours post-LH administration (Goldstein and Sturgis 1961).  The relative 
ascorbic acid content pre- to post-LH treatment increased in the vehicle-only treatment 
group, suggesting the vehicle may have caused the increase in ascorbic acid for unknown 
reasons.  While, both the rbbLHβα and rybLHβα treatments resulted in an overall 
increase in relative ascorbic acid content post-LH treatment, the concentrations were less 
than the vehicle-only control, suggesting an overall reduction.     
The description and use of recombinant bovine LH production in the literature is 
limited.  Kaetzel et al. (1985) reported in vitro activity through an increase in production 
of progesterone after treatment of ovine luteal cells, but did not comment on in vivo 
activity.  Grinberg et al. (2008) incorporated the carboxy-terminal peptide (CTP) and 
compared two subunit fusion orientations (α-CTP-β vs. β-CTP-α), finding the α-CTP-β 
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orientation increased progesterone production from rat granulosa cells.  The CTP is a 
unique ~25 amino acid domain on the placental-derived human chorionic gonadotropin 
(another glycoprotein within the same hormone family as LH) β-subunit, coding for four 
O-linked glycosylation sites (Pierce and Parsons 1981).  The addition of the CTP has 
proven to increase biological activity of recombinant gonadotropins, working with the N-
linked glycosylations already present to protect the protein from proteases within the 
body (Fares et al. 1992; Lemke et al. 2008; Jennings et al. 2009).   
There are a number of other citations reporting recombinant LH use in species 
such as fish, horses, and humans.  The majority of these recombinant LH preparations 
exhibited in vitro activity, but the reports failed to comment on in vivo activity (Gadkari 
et al. 2003; Zmora et al. 2007), or the preparations showed an apparent lack of in vivo 
activity (Hakola et al. 1997; Galet et al. 2001; Ko et al. 2007).      
Conclusions 
 rybLHβα may be more active than rbbLHβα based on the greater reduction of 
LHR gene transcript after one day of incubation in vitro with LH treatment, however 
neither recombinant protein appeared to be as active as the pituitary-derived LH, which 
could be attributed to the total amount of protein administered.  The rat ovarian ascorbic 
acid biological assay did not show an overall depletion of ascorbic acid post-LH 
treatment as expected, but both the recombinant treatments showed a decrease in ascorbic 
acid content when compared to the vehicle-only control group, suggesting any effects 
may have been masked by unknown factors.    
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CHAPTER FOUR 
SUMMARY 
 
 Recombinant bFSH and bLH have been produced from both bacteria and yeast 
heterologous hosts, with most products being extremely pure (>95%).  Bacterial bFSH 
showed biological activity using a rat ovarian weight gain assay, whereas the yeast bFSH 
activity was not determined from the same assay due to unknown complications.  
Recombinant yeast bLH may be more active than recombinant bLH based on the greater 
reduction of LH receptor gene transcript observed after incubation in vitro with LH; 
however, neither recombinant protein appeared to be as active as the pituitary-derived 
LH, which may reflect the consequences of different amounts of total protein 
administered. 
The production of recombinant gonadotropins has changed human assisted 
reproductive technologies, and implementation in the bovine superovulation industry 
could have similar positive effects.  Recombinant bovine FSH was produced originally 
back in the 1980s from a mammalian cell line, but difficulties scaling to commercial 
levels as well as complex government approval (in part a consequence of using a 
mammalian cell product in mammals, which could lead to disease transmission) hindered 
the treatment from gaining popularity.  A recombinant preparation can add a level of 
safety and consistency to bovine superovulation protocols.   
 While Chinese hamster ovary cells (typical mammalian recombinant protein 
production cell line) have proven to produce active gonadotropins, there is still 
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uncertainty about the potential for the fetal bovine serum used in culture media to 
transmit prions and other disease-causing agents.  Using a heterologous expression 
system that requires no fetal bovine serum would resolve this issue.  Lower-order 
organisms that can be cultured in the absence of serum (such as bacteria, yeast, or plants) 
may not be able to produce gonadotropins that possess important post-translational 
modifications found associated with the mammalian product, which may reduce 
biological activity.  This limitation may be overcome by novel gonadotropin delivery 
methods such as a mini-pump or a slow-release implant.  Alternatively, the ability to 
generate large amounts of recombinant protein may allow users to supply a greater dose 
of protein, effectively overcoming half-life concerns. 
 Finally, implementing recombinant gonadotropins into the cattle industry may 
reduce costs associated with these drugs.  Currently, FSH is the most expensive part of 
the bovine superovulation protocol, mainly because of the price of the product, but also 
because of the labor required to administer eight injections of the drug within a span of 
four days.  Providing a more pure product (recombinant preparations), along with 
decreased injection frequency, could benefit the cattle industry substantially.   
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APPENDICES 
Appendix A 
Production of recombinant FSH in a Kluyveromyces lactis heterologous system  
 
Abstract 
Production of recombinant bovine FSH was attempted through the use of the 
Kluyveromyces lactis yeast expression system.  K. lactis is capable of secreting 
glycosylated forms of recombinant proteins into culture media, facilitating production 
and purification.  The bovine FSH gene subunits were cloned into the pKLAC1 
expression cassette and GG799 K. lactis cells were transformed.  Protein expression was 
induced using 2% galactose for 1-4 days at either room temperature or 28oC.  The 
resulting fused protein was not secreted into the culture media and could only be liberated 
from the insoluble fraction of the cell pellet after cell lysis and denaturing purification.   
Introduction 
Recombinant porcine gonadotropin production in heterologous yeast systems has 
been well documented.  The majority of gonadotropin research utilizing yeast as a 
production method has been performed using the Pichia pastoris yeast expression 
system.  Since P. pastoris was the traditional system of choice, a novel approach to 
bovine FSH production was initially chosen, the Kluyveromyces lactis system.  In the K. 
lactis system, genes are cloned downstream of the α-mating factor, which directs the 
secretion of the nascent protein into the growth media during protein induction.  Selection 
of positive transformants is achieved by incorporation of a fungal acetamidase gene that 
100 
converts acetamide to ammonia to use as a nitrogen source for growth on nitrogen-free 
media (New England Biolabs 2007).  The following describes experiments aimed at 
assessing the utility of the K. lactis system in heterologous expression of bovine FSH 
(bFSH). 
Materials and Methods 
The bovine FSH gene subunits were PCR amplified from bovine anterior pituitary 
cDNA and products ligated into the pKLAC1 expression plasmid using a cloning strategy 
designed to generate a fusion protein of an N-terminal 6 histidine (6his) purification tag, 
followed by the β-subunit upstream α-subunit.  The primers can be found in Table D.1.  
The β/α fusion gene was cloned into novel Bgl11 and Sal1 restriction sites found in the 
multiple cloning site.  The resulting construct was transformed into competent DH5α 
bacterial cells for plasmid amplification.  The plasmid (1µg) was then linearized using 
Sac11 and transformants selected by growth at 30oC for 5-7 days on agar plates 
containing 5 mM acetamide.  Protein production for selected clones was induced for 1-4 
days at room temperature or 30oC using 2% galactose.  Cells were harvested by 
centrifugation (1500 x g; 10 min; 4oC) and lysed for 3 min using 0.5 mm glass beads 
(Model 1107900, BioSpec Products Inc, Bartlesville, OK).  Protein was analyzed from 
spent culture media as well as induced cell pellet using 12% SDS-PAGE followed by 
Coomassie Brilliant Blue staining and western blotting.  Blots were blocked for 1 hr in 
1% non-fat milk and 1o mouse α-6his antibody (1:2000) or 1o α-ovine FSH (1:250) added 
for 1 hr.  Primary antibodies were detected with goat-α-mouse (GαM) horseradish 
peroxidase (HRP; 1 hr).  HRP was visualized using SuperSignal® West Pico 
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Chemiluminescent Substrate Kit (Pierce®, Rockford, IL).  Denaturing purification was 
performed with 8 M urea and purification was performed using nickel affinity 
chromatography.   
Results 
 After 1-4 days of protein induction at either room temperature or 30oC, 
recombinant yeast bFSHβα (rybFSHβα) protein was not detected in the spent culture 
media, and was only detected in the cell pellet fraction (Figure A.1, lanes 1 and 3).  After 
a large-scale expression (Figure A.2) and further analysis of the cell pellet by denaturing 
purification utilizing 8 M urea, the recombinant protein was detectable in the soluble 
fraction (Figure A.3), but was refractory to purification by nickel affinity 
chromatography. 
 
Figure A.1 Small-scale expression study of rybFSHβα-6his in K. lactis yeast.  Protein was 
induced with the addition of 2% galactose at either room temperature or 30oC for 1-4 days.  
Analysis was performed on small samples of pelleted cells (CP) or spent culture supernatant (CS) 
using 1o mouse α-6his (1:2000), 2o GαM HRP (1:5000). 
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Figure A.2 Western blot of rybFSHβα-6his protein expression from K. lactis GG799 cells.  
Protein expression was induced for 1 day at RT. Lane 1: yeast induction culture cell pellet. Lane 
2: yeast induction culture supernatant.  Protein detected using 1o α-6his antibody (1:2000) and 2o 
GαM HRP (1:5000).  
 
 
Figure A.3 Western blot detecting rybFSHβα-6his produced from K. lactis after denaturing 
purification.  Protein expression was induced for 3 days at room temperature and yeast cell pellet 
was beaten using 0.5 mm glass beads to facilitate lysis. Lane 1: yeast culture supernatant post-
induction. Lane 2: soluble fraction after cell pellet lysis. Lane 3: insoluble fraction after cell pellet 
lysis. Protein detected using 1o α-ovine FSH antibody (1:500) and 2o GαM HRP (1:2000). 
 
Discussion 
 The K. lactis expression cassette was chosen because it was a novel expression 
system for bovine gonadotropin production, and for its ability to channel nascent 
recombinant proteins through the secretory pathway into the culture media during protein 
103 
induction.  After manipulating a multitude of expression procedures (combinations of 
size of culture and induction temperature and length), the rybFSHβα was liberated from 
the insoluble fraction of the induced cell pellet only after urea denaturation.  Denaturation 
is not ideal for industrial scale production, so this method of yeast recombinant protein 
production was abandoned for the Pichia pastoris expression system, in hopes of 
producing a secreted recombinant protein product. 
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Appendix B 
Optimizing recombinant bovine FSH protein production through manipulation of subunit 
orientation 
 
Abstract 
 In an attempt to optimize protein production from bacterial expression systems, 
the order of FSH subunit genes (α first, followed in fusion with β, or with the order 
switched) and the addition of a linker sequence between the subunits were considered.  
After successful cloning, the FSH expression cassette was transformed into a number of 
bacterial strains in order to explore optimized soluble protein expression.  None of these 
alterations resulted in an efficient method to produce recombinant bacterial-derived 
bovine FSH.   
Introduction 
Protein subunit gene orientation and linking sequence  
FSH is produced by mammals as two separate subunits that are non-covalently 
associated post-translation (Pierce and Parsons 1981).  In initial recombinant protein 
production efforts, gonadotropins were produced in this way, as two separate products 
that were associated post-production (Kaetzel et al. 1985; Keene et al. 1989).  This 
method was effective but required multiple production steps.  Subsequent research has 
proven that FSH can be produced as a single construct, with both subunits being 
expressed in tandem (Olijve et al. 1996; D’Antonio et al. 1999).  The question then 
becomes if a specific subunit orientation in a fusion construct favors greater solubility or 
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activity.  Further, adequate folding of the tethered protein may be inhibited because of the 
physical constraints of the linker.  Additionally, there may be a balance between linker 
size required to facilitate appropriate flexibility while not being so large as to interfere 
with activity.  Protein linker sequences have traditionally incorporated neutral amino 
acids such as glycine which have a low tendency for forming α-helices or β-sheets and 
have been as short as possible.  Linking sequences can also incorporate purification tags, 
glycosylation sites, or protease sites (Robinson and Sauer 1998, Crasto and Feng 2000).  
The following set of experiments was conducted to produce multiple FSH constructs with 
varying orientations of subunits and linking sequences.   
Protein expression in multiple bacterial strains 
 In order to optimize soluble protein expression, multiple bacterial host strains 
were considered.  A summary of the bacterial strains that were used, along with some key 
features, can be found in Table B.1.  All of these strains were chosen because they 
inducibly express T7 RNA polymerase.  The Rosetta bacterial strains express extra tRNA 
(AGG, AGA, AUA, CUA, CCC, and GGA) that bacteria do not typically harbor at high 
concentrations.  This can enhance the production of mammalian recombinant proteins.  
The RosettaGami strain is engineered to increase the formation of disulfide bonds to aid 
in protein folding and stability.  The pLysS plasmid found in the RosettaBlue and II 
strains expresses the T7 lysozyme, a protein which binds and represses T7 RNA 
polymerase until expression is induced to prevent leaky expression of potentially toxic 
heterologous products (Zhang and Studier 1997). 
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Table B.1 Bacterial strains used to explore recombinant bovine FSH induction. 
Bacterial Strain ↑TE* T7 lysozyme Extra tRNA ↑Disulfide bonds 
NovaBlue(DE3) √   
 
RosettaBlue(DE3) √ √ √ 
 
RosettaII(DE3)  √ √ 
 
RosettaGami(DE3) 
  √ √ 
*Abbreviations: TE: transformation efficiency 
Materials and Methods 
 Bovine FSH (bFSH) α- and β-subunit genes were PCR amplified from bovine 
anterior pituitary cDNA and novel restriction sites added as a result (see Tables D.2 and 
D.3 for primer sequences).  After production, the two purified subunit genes were ligated 
together in one of two orientations: β-subunit upstream of α-subunit, or vice versa (Figure 
B.1), and the full length fusion amplified by PCR using flanking primers (see Figure B.1, 
rows A and B, for primer orientations and Tables D.2 and D.3 for primer sequences).  
Alternatively, a triple myc tag (three myc tags in fusion, 5’ 
GAACAAAAACTCATCTCAGAAGAGGATCTG3 3’) was ligated between the two 
subunits, again in either β/α or α/β configuration (Figure B.1, rows C and D, and Table 
D.4 for primer sequences).  These constructs were transformed into the shuttle vector 
pGEMEZ-T for gene amplification.  Subsequently, the bFSH fusion gene was digested 
from the shuttle vector and ligated into the vector pGEX4T-1 and sequenced.  Plasmids 
were transformed by electroporation (ECM830, BTX, Holliston, MA) into either 
BL21(DE3) bacteria, or one of the aforementioned alternative bacterial cell lines (Table 
B.1).  Cultures were grown to OD600 of 0.6 in terrific broth media (1% tryptone, 2.5%  
107 
 
Figure B.1 Pictorial representation of various expression plasmids produced in order to 
optimize bFSH subunit orientation, and to insert a linking sequence between the two 
subunits. 
 
yeast extract, 0.4% glycerol, 17 µM KH2PO4, 72 µM K2HPO4) at 37oC and protein 
expression induced by addition of 250 µM IPTG at either room temperature or 37oC for 
either 3 h or overnight.  bFSH was purified using affinity chromatography, taking 
advantage of the GST tag provided by the pGEX4T-1 vector engineered at the N-
terminus of the protein.  Purification fractions and induced cell pellets were analyzed by 
12% SDS-PAGE stained with Coomassie Brilliant Blue and western blotting.  For 
westerns, protein was transferred from acrylamide gels to nitrocellulose at 16 V for 40 
min (TransBlot SD Semi Dry Transfer Cell, BioRad, Hercules, CA).  Blots were blocked 
(1% non-fat milk) for 1 hr, and 1o α-GST-biotin (1:2000) or 1o α-ovine FSH (1:250) 
antibodies were incubated for 1 hr at RT, followed by 2o α-biotin horseradish peroxidase 
(HRP; 1:5000) incubated for 1 hr at RT.  HRP was visualized using SuperSignal® West 
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Pico Chemiluminescent Substrate Kit (Pierce®, Rockford, IL).  Protein concentration 
was determined using a BCA Assay kit (Pierce®, Rockford, IL). 
Results and Discussion 
Subunit orientation 
 Following the identification of positive clones of both bFSH subunit orientation 
plasmids, protein production was initiated.  More information on bFSHβα production can 
be found in Chapter 2.  Briefly, bFSHβα-GST protein was produced from BL21(DE3) 
bacterial cells, but a frame-shift mutation in the expression plasmid caused an excess of 
free GST to be produced rather than the GST-fusion protein.  Re-cloning efforts were 
unsuccessful.  bFSHαβ-GST protein was isolated from the soluble fraction after bacterial 
lysis (Figure B.2), and was concentrated at 825 µg/ml (purity estimated at ~80%).   
 
 
Figure B.2 Wash purification fractions of rbbFSHαβ.  A: α-GST antibody (1:2000). B: α-
ovine FSH antibody (1:500).  Protein concentration was assessed at 825 µg/ml and purity 
estimated at 80%. 
 
 
 
109 
Linker sequence introduction  
Initial attempts at cloning a myc3 linker between the subunits employed a myc 
oligomer with Kpn1 sites at both termini.  This approach was designed to clone the myc3 
tag using the Kpn1 site employed in the original fusion ligation (β/α or α/β).  Introduction 
of the myc3 tag using this approach worked, but all myc inserts were in the wrong 
orientation, introducing a stop codon where the myc3 tag should have been.  A second 
cloning strategy was used, employing directional cloning using two different restriction 
sites for the 5’ and 3’ ends of the myc3 tag.  This strategy failed for reasons that are not 
clear, with the sequencing of every construct being negative.   
Alternative bacterial strains for bFSHβα production 
 Expression of bFSHβα was induced in five bacterial strains, the first being 
BL21(DE3).  Soluble protein was not attained from this cell line, so the other four cell 
lines were utilized.  Hourly expression samples from small-scale induction cultures using 
each bacterial strain can be found in Figure B.3.  The two strains that yielded the most 
protein (NovaBlue and Rosetta II, Figure B.3, rows A and C) were then induced in larger 
cultures, and affinity chromatography utilizing the N-terminus GST tag was performed.  
The resulting protein did not bind the GST column and was found in the flow-through 
and early wash steps (Figure B.4).  Re-sequencing revealed a frame-shift in the GST 
gene, resulting in the loss of a functional protein, explaining loss of binding.  At this 
point, re-cloning would be necessary and expression studies would follow to determine 
conclusively the value of subunit gene orientation and linker use. 
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Figure B.3 Expression profiles of rbbFSHβα in 4 bacterial strains.  Protein expression was 
induced addition of 250 µM IPTG and samples of uninduced and induced cultures were taken 
every hour for 3 hours. Protein analysis was performed using Western blotting: 1o α-GST 
antibody (1:2000) and 2o α -biotin (1:5000). A. NovaBlue(DE3). B. RosettaBlue(DE)3pLysS. C. 
RosettaII(DE3)pLysS. D. RosettaGami(DE3)pLacI.      
 
 
 
Figure B.4 Large-scale expression of rbbFSHβα from NovaBlueDE3 bacterial cells.  Protein 
was induced using 250 µM IPTG for 3 hours at 37oC.  Protein analysis was performed using 
Western blotting: α-GST antibody (1:2000) and 2o α -biotin (1:5000).  Protein was seen in flow 
through (FT) fractions, all washes (W1-3) and the first two elution fractions (E1-2), suggesting 
protein did not bind GST purification column. 
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Conclusions 
 The production of β/α subunit orientation protein was unsuccessful due to a 
frame-shift mutation.  Protein in the α/β subunit orientation was produced from bacterial 
cells, but purification efforts were not pursued.  Finally, any attempts to insert a linker 
sequence between the two subunits were unsuccessful.    
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Appendix C 
Purification and characterization of recombinant human glucokinase 
 
Abstract 
 Glucokinase (GK) is the key glucose sensor in mammals, metabolizing glucose 
into glucose-6-phosphate.  Mutation or incorrect splicing of the human GK (hGK) gene 
can lead to multiple forms of mature-onset of diabetes in the young (MODY).  Activators 
of the GK enzyme would potentially be useful as a drug therapy for MODY, type II 
diabetes, and glucose homeostasis.  Here, we describe the expression and purification of 
recombinant hGK for use in screens aimed at identifying both inhibitors and activators of 
this enzyme.  The hGK gene was cloned from cDNA into the pQE30 expression plasmid 
and transformed into M15(pREP) E. coli bacterial cells for induction of protein 
expression.  A battery of assays was performed with purified hGK to test for enzyme 
activity, optimal storage conditions, and use of phosphoryl donors.  Finally, compounds 
from a screen for inhibitors of a related enzyme, Trypanosoma brucei hexokinase 
(TbHK), were tested against hGK for inhibition and activation.      
Introduction 
GK (also known as hexokinase IV) is one of four hexokinases found in mammals.  
GK is the rate limiting enzyme for the phosphorylation of glucose to glucose-6-
phosphate, which is the first step in glycolysis.  hGK is expressed in liver, brain, gut 
endothelium, and pancreatic β cells, with the latter being the location of insulin regulation 
associated with glucose uptake from the circulation, facilitated by GLUT2 transporter 
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(Osbak et al. 2009; Pal 2009).   GK is regulated in the pancreas β cells by the availability 
of its substrate, glucose, and controls the amount of glucose that enters into glycolysis 
(Giuffrida and Reis 2005).  As a consequence of mutation, some of which leads to 
generation of splice variants (hGK is encoded in 12 exons), a number of hyper- and hypo-
glycemic disorders can be attributed to hGK (Osbak et al. 2009).   
 MODY is a disorder caused by mutation of the hGK gene which results in 
pancreatic β cell disfunction (Osbak et al. 2009; Colom and Corcoy 2010).  MODY 
phenotypes are based on type and frequency of mutation of hGK gene and HNF 
(hepatocyte nuclear factor) genes, which play a fundamental role in the function of 
pancreatic β cells (Giuffrida and Reis 2005).  In milder forms (MODY2), less insulin (up 
to 60% reduction) is secreted as a result of inappropriate glucose sensing in the pancreas, 
as well as a hepatic glucose phosphorylation deficiency (Velho et al. 1996).  The mild-
form disorder typically presents with mild fasting hyperglycemia and can usually be 
controlled by diet alone.  More severe forms (MODY3) usually require insulin 
replacement therapy or oral hyperglycemic agents, and those affected may be at risk for 
vascular disease (Giuffrida and Reis 2005; Osbak et al. 2009).  Activators of hGK could 
be an ideal treatment for some types of MODY in efforts to increase insulin secretion 
(Osbak et al. 2009). 
hGK activators may also assist in control of type II diabetes, a disorder noted by a 
lack of ability to make or utilize insulin in the pancreatic β cells in obese adults.  This 
leaves excess glucose and potentially excess insulin in the circulatory system, causing 
problems such as lipid buildup, renal failure, and vascular neuropathy.  Activation of 
115 
hGK may assist by stimulating the usage of glucose in the pancreas or liver.  Glucose 
activators may also be useful for neurons in the brain that are responsible for sensing 
changes in glucose levels within the body and maintaining glucose homeostasis (Pal 
2009).  Here, we have screened a panel of compounds known to bind to hexokinases 
(identified in a screen for inhibitors of TbHK) for activators and inhibitors of hGK. 
Materials and Methods 
Reagents 
Quercetin dehydrate (QCN; 3,3’,4’,5,7-pentahydroxyflavone) was purchased from 
Spectrum Chemical Manufacturing Corporation (Gardena, CA).  Lonidamine (LND; 1-
(2,4-dichlorobenzyl)-1,H-indazol-3-carboxylic acid) was purchased from Sigma-Aldrich 
(St. Louis, MO).  All HTS compounds were supplied by University of Kansas 
Specialized Chemistry Center (Lawrence, KS). 
Expression of hGK 
hGK cDNA was purchased from Open Biosystems (Huntsville, AL).  PCR was 
used (Forward primer 5’GATC GGA TCC CTG GAC GAC AGA GCC 3’; Reverse 
primer 5’ GATC AAG CTT CTG GCC CAG CAT ACA GGC 3’) to amplify the ORF, 
and cloned into pQE30 using BamH1 and Hind111 restriction sites engineered into the 
primers for cloning.  This construct generates an N-terminal RGS(His)6 tag for affinity 
purification.   
Plasmid was then transformed into M15(pREP) E. coli cells for protein 
expression.  Briefly, a 1 L terrific broth culture of M15(pREP) harboring pQE30hGK was 
grown to an OD600 of 0.6 and protein expression induced for 4 hours at 37oC by addition 
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of 1 mM IPTG.  Bacteria were collected by centrifugation (10,000 x g, 30 min, 4oC) and 
the resulting cell pellet lysed in 1% tosyl-L-lysine chloromethyl ketone (50 mg/mL), 2 
mg/mL lysozyme, 0.1% Triton X-100, and 10 mM glucose.  The resulting lysate was then 
centrifuged (10,000 x g, 30 min, 4oC) and protein from the soluble fraction purified using 
nickel affinity chromatography (Ni-NTA Agarose, Qiagen) as directed by the 
manufacturer.  Purified hGK was analyzed on 15% SDS-PAGE and Coomassie staining 
or western immunoblotting using an α-RGS(His)6 antibody and chemiluminesence.  
Protein was stored at -80oC in 20% glycerol. 
Enzyme assays 
Enzyme activity was determined using a previously described HK assay (Misset 
et al. 1984; Morris et al. 2002).  Briefly, the assay employed glucose-6-phosphate 
dehydrogenase (0.1 unit/assay, EMD Biosciences, Inc, San Diego, CA) to convert 
glucose-6-phosphate (G6-P) generated by hGK to 6-phoshogluconate with coincident 
reduction of NADP to NADPH.  Reagent final concentrations in the 200 µl reactions 
were: 50 mM triethanolamine (TEA), 33 mM MgCL2, 20 mM glucose, 5.25 mM ATP, 
and 0.75 mM NADP.  Assays were performed in a 96-well microtiter plate and read in a 
GENios spectrophotometer (Phenix Research Products, Hayward, CA).  
Inhibition/Activation assays were performed by the addition of various compounds to the 
aforementioned HK assay with a 10 minute incubation of hGK and inhibitor prior to 
addition of remaining assay components.   
Results 
Enzyme purification 
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hGK was purified from the soluble fraction of the bacterial cells using nickel 
affinity purification.  Protein expression was assessed by SDS-PAGE and western 
blotting (Figure C.1).  hGK was identified as a 55 kDa band by Coomassie staining 
consistent with its predicted size and protein purity was estimated at >99%.  Western 
blotting confirmed the species to be a RGS-6His-bearing polypeptide.  Elution fractions 
from the purification were pooled and stability was tested at various temperatures with 
and without 20% glycerol.  Optimal stability was found at -80oC with 20% glycerol.  
After 1 month, 76% of the initial enzyme activity remained (data not shown).  Using 
native gel electrophoresis, hGK was found to be a monomer unlike the Trypanosoma 
brucei hexokinases which form a hexamer (Chambers et al. 2008).    
 
 
Figure C.1 Recombinant hGK protein induced from E. coli bacterial cells overnight at RT.  
Cell pellet was lysed and protein was purified from soluble fraction using nickel affinity 
chromatography. A: Coomassie stain of purified fraction. B: Western blot of purified purification 
fraction using 1o α-6his (1:2000), 2o GαM HRP (1:5000). 
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Enzyme kinetics 
After positive identification, the protein was analyzed for its enzymatic activity by 
enzyme coupled HK activity assay.  hGK was found to have a specific activity of 872.6 
mmol min-1 mg-1, with Km of 9.36 mM for ATP and 0.258 mM for glucose.      
Phosphoryl Donors 
To further interrogate the enzyme activity, alternative phosphoryl donors were 
considered, including ADP, AMP, and ITP.  None of these supported enzyme activity (as 
detected by glucose-6-phosphate production).   
Enzyme assay optimization 
HKs from other systems have been reported to be sensitive to pH, but protected 
from pH-based inactivity by the addition of glyerol-3-phosphate (unpublished 
observation).  Under acidic conditions less than pH 6.0, hGK enzyme is inactivated.  The 
addition of glycerol-3-phosphate (20 mM) restores detectable activity.  Notably, 
inactivation is the result of excess ATP, as reduction of ATP under acidic (pH 6.0) 
conditions limits inactivation (Figure C.2).  These observations suggest that hGK, like the 
TbHK, has an allosteric site for nucleotide binding that is exposed under acidic 
conditions.       
Inhibition/Activation Assays 
A number of known and potential inhibitors of hexokinase were added to the HK 
assay to assess their effects on hGK.  LND and fumurate, both reported to inhibit TbHK, 
were modest inhibitors (IC50 = 538 µM and 66% at 10 µM, respectively) while QCN was 
more potent with an IC50 = 8 µM.  A number of other compounds were analyzed and  
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Figure C.2 Human GK activity under acidic conditions. Activity of hGK was assayed under 
acidic conditions (pH 6.0) and in the presence or absence of glycerol-3-phosphate, and with either 
5 mM or 0.5 mM ATP. Values are compared to hGK under normal physiologic conditions (pH 
7.4), which is set to 100% activity. 
 
found to have little inhibitory effects (at 1 mM), including myristate, butyrate, succinate, 
and malate.  hGK was also used as part of a collaborative effort.  In a computer screen of 
T. brucei HK inhibitors, a number of potent hGK inhibitors were identified including 
SID87326000 and SID85786737 (91.5 ± 1.9% and 56.1 ± 0.66% inhibition at 10 µM, 
respectively).  Because these are single concentration points, structure activity 
relationships (SAR) are difficult to resolve.  Activators, including SID97302142 and 
SID97302151 (27.0 ± 2.8% and 23.1 ± 5.6% activation at 10 µM, respectively) were also 
identified.  The results of these inhibition assays are found in Table C.1. 
 
120 
Table C.1 hGK activity in the presence of potential inhibitor or activator compounds. 
 
Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
1 17387000 
 
30.8 ± 9.0 
2 85285421 
 
39.6 ± 1.9 
3 85285422 
 
50.1 ± 3.0 
4 85285424 
 
37.2 ± 2.6 
5 85742030 
 
28.2 ± 9.8 
6 85742031 
 
8.84 ± 4.49 
7 85742032 
 
28.9 ± 6.9 
8 85742033 
 
34.9 ± 2.0 
 
Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
9 85742034 
 
0.0 
10 85747718 
 
35.6 ± 8.7 
11 85752767 
 
++ 
12 85752848 
 
37.8 ± 3.4 
13 85786735 
 
48.8 ± 6.0 
14 85786736 
 
56.2 ± 0.88 
15 85786737 
 
56.1 ± 0.66 
16 85786738 
 
55.6 ± 3.8 
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Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
17 85786739 
 
55.0 ± 1.2 
18 85786740 
 
49.9 ± 2.5 
19 87225565 
 
+ 
20 87225566 
 
0.0 
21 87225567 
 
11.37 ± 9.6 
22 87225568 
 
+ 
23 87225569 
 
0.0 
24 87225570 
S
N
O
F
Cl
 
0.0 
 
Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
25 87325999 
 
41.2 ± 6.8 
26 87326000 
 
65.6 ± 5.4 
27 87326001 
 
91.5 ± 1.9 
28 87326002 
 
51.9 ± 14.6 
29 87326003 
 
45.7 ± 13.3 
30 87350305 
 
0.0 
31 87350306 
 
0.0 
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Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
32 87350307 
 
13.6 ± 7.8 
33 87350308 
 
22.1 ± 4.9 
34 87350309 
 
0.0 
35 87350310 
 
33.8 ± 1.1 
36 87350311 
 
36.2 ± 4.4 
37 87350312 
 
54.0 ± 11.6 
38 87550699 
 
0.0 
 
Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
39 87550700 
 
0.0 
40 87550701 S NH
O
N
O
O
 
0.0 
41 87550702 
 
0.0 
42 87550703 
 
0.0 
43 87550704 
 
0.0 
44 87550705 
 
0.0 
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Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
45 90944616 
 
0.0 
46 90944617 
 
16.9 ± 14.3 
47 90944618 
 
++ 
48 90944619 
 
+ 
49 90944620 
 
+ 
50 90944621 
 
++ 
51 90944622 
 
++ 
 
Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
52 90944623 
 
0.0 
53 92126107 
 
38.3 ± 6.65 
54 92126109 
 
32.9 ± 15.0 
55 92126110 
 
33.8 ± 8.23 
56 92126111 
 
23.8 ± 7.19 
57 92126112 
 
22.2 ± 17.6 
58 92126113 
 
14.3 ± 3.14 
59 92126114 
 
0.0 
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Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
60 92126115 
 
40.1± 10.5 
61 92708914 
 
26.1 ± 1.54 
62 92708915 
 
14.1 ± 9.5 
63 92708916 
 
8.01 ± 3.9 
64 92708917 
 
+ 
65 92708918 
 
+ 
66 92708919 
 
++ 
67 92708920 
 
32.2 ± 24.3 
 
Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
68 92708921 
 
++ 
69 92708922 
 
0.0 
70 92708923 
 
0.0 
71 92708977 
 
0.0 
72 93575714 
 
0.0 
73 93575715 
 
16.7± 2.3 
74 93575717 
 
0.0 
75 93575720 
 
0.0 
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Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
76 93575721 
 
10.9± 6.5 
77 93575722 
 
0.0 
78 93575723 
 
0.0 
79 93575724 
 
38.4± 0.59 
80 93575725 
 
0.0 
81 93575726 
 
0.0 
82 
93575727 
(24797131) 
 
 
9.26 ± 3.5 
83 93575728 
 
0.0 
 
Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
84 93575729 
 
0.0 
85 93618290 
 
+ 
86 93618291 
 
7.02 ± 4.5 
87 93618292 
 
0.0 
88 93618293 
 
0.0 
89 93618294 
 
0.0 
90 93618295 
 
++ 
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Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
91 93618296 
 
NS 
92 93618297 
 
0.0 
93 93618298 
 
20.5 ± 14.9 
94 93618299 
 
0.0 
95 93618300 
 
24.38 ± 4.9 
96 93618301 
 
0.0 
97 93618302 
 
22.1 ± 8.1 
 
Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
98 93575716 
 
30.6 ± 7.1 
99 93575718 
 
++ 
100 93575719 
 
10.29 ± 2.6 
101 96022034 
 
30.3 ± 8.1 
102 96022035 
 
11.1 ± 8.5 
103 96022036 
 
18.2 ± 5.5 
104 96022037 
 
0.0 
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Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
105 96022038 
 
++ 
106 96022039 
 
0.0 
107 96022040 
 
0.0 
108 96022041 
 
+ 
109 96022042 
 
+ 
110 96022043 
 
0.0 
 
Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
111 96022044 
 
14.5 ± 3.1 
112 96022045 
 
0.0 
113 97302133 
 
++ 
114 97302134 
 
++ 
115 97302135 
 
++ 
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Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
116 97302136 
 
0.0 
117 97302137 
 
+ 
118 97302138 
 
++ 
119 97302139 
 
+ 
120 97302141 
 
++ 
121 97302142 
 
+++ 
122 97302143 
 
0.0 
 
Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
123 97302144 
 
0.0 
124 97302145 
 
0.0 
125 97302146 
 
++ 
126 97302147  
 
+ 
127 97302148 
 
++ 
128 97302149 
 
+ 
129 
 
Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
129 97302150 
 
++ 
130 97302151 
 
+++ 
131 97302152 
 
++ 
132 97302153 
 
++ 
133 97302154 
 
0.0 
134 96022041 
 
+ 
 
Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
135 97302155 
 
5.21 ± 3.8 
136 99222681 
 
0.0 
137 
99222682 
and 
99344412 
 
++ 
138 99222683 
 
13.1 ± 9.7 
139 99222684 
 
+ 
140 99222685 
 
+ 
141 99222686 
 
+ 
142 99222687 
 
15.8 ± 8.2 
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Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
143 99222688 
 
+ 
144 99222689 
 
+++ 
145 99222690 
 
0.0 
146 99222691 
 
++ 
147 99222692 
 
++ 
148 99222693 
 
++ 
149 99222694 
 
++ 
 
Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
150 99222695 
 
++ 
151 99222696 
 
23.1 ± 8.3 
152 99234241 
 
+ 
153 99234242 
 
16.8 ± 3.9 
154 99234243 
 
+ 
155 99234244 
 
+++ 
156 99234245 
 
+ 
157 99234246 
 
++ 
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Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
158 99234247 
 
+ 
159 99234248 
 
+++ 
160 99234249 
 
+++ 
161 99234250 
 
+ 
162 99234251 
 
14.9 ± 8.9 
163 99234262 
 
30.3 ± 13.4 
164 99234263 
 
0.0 
165 99234264 
 
19.5 ± 8.4 
 
Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
166 99245521 
 
++ 
167 99245522 
 
11.5 ± 6.3 
168 99245523 
 
12.2 ± 4.0 
169 99245524 
 
27.6 ± 7.2 
170 99245525 
 
12.5 ± 5.5 
171 99245526 
 
+ 
172 
99245527  
and 
99344410 
 
13.5 ± 10.0 
173 99344409 
 
+ 
132 
 
Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
174 99344411 
 
30.1 ± 6.9 
175 99344413 
 
17.9 ± 7.5 
176 99344414 
 
21.1 ± 8.4 
177 99344415 
 
26.0 ± 8.3 
178 99344416 
 
22.9 ± 6.6 
179 99344417 
 
35.4 ± 8.0 
180 99380765 
 
17.6 ± 3.9 
 
Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
181 99380766 
 
22.3 ± 6.4 
182 99380767 
 
26.2 ± 4.8 
183 99380768 
I
I
OH
H
N
O
Cl Cl
CN
 
24.3 ± 1.2 
184 99380769 
 
32.1 ± 7.8 
185 99380770 
 
25.9 ± 7.8 
186 99380771 
 
0.0 
133 
 
Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
187 99380772 
N
H
OH
O
OMe
Cl
 
22.2 ± 0.62 
188 99380773 
 
28.4 ± 5.3 
189 99437303 
 
9.2 ± 0.61 
190 99437304 
 
10.6 ± 7.8 
191 99437306 
 
11.9 ± 7.2 
192 99437307 
 
+ 
 
Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
193 99437308 
 
++ 
194 99460890 0.0 
195 99460891 IC50 = 2.2± 0.5 µM 
196 99437306 
 
IC50 = 48.3 
± 6.9 µM 
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Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
197 99460892 
 
0.0 
 
Entry 
PubChem 
SID Structure 
% hGK 
Inhibition 
(10 µM) 
198 99460893 
 
0.0 
199 103023816 
 
0.0 
 
*Abbreviations: NS = not soluble; IC50 = Concentration 
required for 50% inhibition; + = 0-10.9 % activation; ++ = 
11-20.9% activation; +++ = >21% activation. 
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Discussion 
A number of compounds found in the high throughput screen were found to 
activate hGK.  As previously mentioned, drug therapies aimed at activating hGK may be 
useful in multiple diabetes disorders, including MODY and type II diabetes.  Small 
molecules deemed effective at activating hGK have been previously discovered, and 
trials in rats have shown that these molecules are able to reduce circulatory glucose levels 
and increase insulin release.  Human pharmacological studies with these molecules have 
mirrored these results (Matschinsky and Porte 2010).  
 Alongside the discovered activators, a number of compounds had no consequence 
on the activity of hGK.  This is important because the intent of the high throughput 
screen was to identify potential inhibitors of T. brucei hexokinase.  To develop a drug 
target against trypanosomiasis (or African sleeping sickness, prevalent in Sub-Saharan 
Africa), candidate compounds should inhibit the trypanosome hexokinase while not 
impacting the activity of the hGK enzyme.  Efforts are still underway to discover the 
ideal chemistry for this drug target.   
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Appendix D 
Oligonucleotide primer sequences for gene amplification and qRT-PCR  
 
Table D.1 Oligonucleotide primer sequences for amplification of bovine FSHβα into K. lactis 
yeast protein expression cassette, pKLAC1. 
Primer Sequence 
bFSHβ 
For 5’ GATCAGATCTAGAGGATCGCATCACCATCACCATCACAAGTCTGTCCAGTTC 3’ 
Rev 5’ GATCGGTACCTTCTTTGATTTCCCTGAAGG 3’ 
  
bFSHα 
For 5’ GATCGAATTCGATTACTACAGAAAATATGC 3’ 
Rev 5’ GATCGTCGACTTAGGATTTGTGATAATAACAAG 3’ 
 
 
Table D.2 Oligonucleotide primer sequences for amplification of bovine FSH β subunit, LH 
β subunit, and the common α subunit in E. coli bacterial protein expression cassette, 
pGEX4T-1. 
Primer Sequence 
bFSHβ For 5’ GATCGGATCCAAGTCTGTCCAGTTC 3’ 
Rev 5’ GATCGGTACCTTCTTTGATTTCCCTGAAGG 3’ 
  
bLHβ For 5’ GATCGGATCCGAGATGTTCCAGGGAC 3’ 
Rev 5’ GATCGGTACCGAGGAAGAGGATGTC 3’ 
  
α-subunit For 5’ GATCGAATTCGATTACTACAGAAAATATGC 3’ 
Rev 5’ GATCCTCGAGGGATTTGTGATAATAACAAG 3’ 
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Table D.3 Oligonucleotide primer sequences for amplification of bovine FSHαβ in E. coli 
bacterial expression cassette, pGEX4T-1. 
Primer Sequence 
bFSHα For 5’ GATCGGATCCGATTACTACAGAAAATATGC 3’ 
Rev 5’ GATCGGTACCGGATTTGTGATAATAACAAG 3’ 
  
bFSHβ For 5’ GATCGGTACCAAGTCTGTCCAGTTCTG 3’ 
Rev 5’ GATCCTCGAGTTCTTTGATTTCCCTGAAGG 3’ 
 
 
Table D.4 Oligonucleotide primer sequences for triple myc tag (linker sequence) insertion 
between bovine FSH subunits. 
Primer Sequence 
Myc3 For 5’ GATCGGTACCGAGCAAAAGCTCATTTC 3’ 
Rev 5’ GATCGGTACCAAGATCCTCCTCGGA 3’ 
 
 
Table D.5 Oligonucleotide primer sequences for amplification of bovine FSH β subunit, LH 
β subunit, and the common α subunit in P. pastoris yeast protein expression cassette, 
pPICZαA. 
Primer Sequence 
bFSHβ For 5’ GATCGAATTCAAGTCTGTCCAGTTCTGTTTC 3’ 
Rev 5’ GATCGGTACCTTCTTTGATTTCCCTGAAGG 3’ 
  
bLHβ For 5’ GATCGAATTCGAGATGTTCCAGGGAC 3’ 
Rev 5’ GATCGGTACCGAGGAAGAGGATGTC 3’ 
  
α-subunit For 5’ GATCGGTACCGATTACTACAGAAAATATGC 3’ 
Rev 5’ GATCCCGCGGGGATTTGTGATAATAACAAG 3’ 
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Table D.6 Oligonucleotide primer sequences for qRT-PCR. 
Primer Sequence Size (bp) Accession no. 
GAPDH For 5’ AGCGAGATCCTGCCAACATCAAG 3’ 221 AJ000039 
            Rev 5’ GCAGGAGGCATTGCTGACAATCT 3’ 
 
 
 
CYP19A1 For 5’ GAAGTGCTGAACCCAAGGCATTAC 3’ 171 Z32741 
            Rev 5’ AATGAGGGGCCCAATTCCCAGA 3’ 
 
 
 
FHSR For 5’ TCACCAAGCTTCGAGTCATCCCAA 3’ 189 NM_174061 
           Rev 5’ TCTGGAAGGCATCAGGGTCGATGTA 3’ 
 
 
 
LHR For 5’ GCATCCACAAGCTTCCAGATGTTACGA 3’ 204 NM_174381 
         Rev 5’ GGGAAATCAGCGTTGTCCCATTGA 3’   
 
